Androst-4-en-19-ols

ABSTRACT

Derivatives of androst-4-en-19-ol are useful for enhancing libido and related psychic attitudes.

CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. application Ser. No.329,849, filed Feb. 5, 1973.

FIELD OF THE INVENTION

This invention relates to derivatives of androst-4-en-19-ol, to theirpreparation and to their use in primates to enhance an impaired ordiminished libido and to improve related psychic attitudes associatedtherewith.

DESCRIPTION OF THE PRIOR ART

U.S. Pat. No. 2,819,276 discloses 3,19-dihydroxy-4-androsten-17-oneuseful for its estrogenic properties. Additionally, the referencediscloses the corresponding 3-ketones. The 3,19-dihydroxy steroids arestated to be useful as intermediates for the preparation of 19-hydroxyand 19-norsteroids. The 19-norsteroids are stated to possess anabolicand hypotensive action. The most closely related novel compounds of thisinvention differ from the prior art in possessing an additional ethergroup in either the 3,17 and/or 19-positions. In addition the compoundsof the present invention possess a totally different and surprisingutility from that which is disclosed in the prior art.

U.S. Pat. No. 3,278,528 discloses the preparation of 5α-halo-4β,19-oxidoandrostanes, pregnanes and spirostanes. The reference teaches theconversion of these compounds to certain3,17-substituted-androst-4-en-19-ols and 3,17,19-substitutedandrost-4-enes which are closely related to the novel compounds of thisinvention. The prior art compounds are stated to be useful asanabolic-androgenic agents having a favorable anabolic-androgenic ratio.Additionally they are stated to have "anti-estrogenic,anti-gonadotrophic, anti-fibrillatory and appetite stimulatingproperties . . . lower the blood cholesterol level, relieve premenstrualtension and suppress the output of the pituitary gland." However, themost closely related novel compounds of this invention all differ inthat one or more of the 3,17 and/or 19-positions must be etherified.Furthermore the novel compounds described herein possess the remarkableability of enhancing the libido of primates, a utility not previouslydescribed nor associated with the class of androst-4-en-19-ols and itsderivatives.

Rao and Axelrod, J. Org. Chem, 27, 4694-6 (1962) describe thepreparation of the 17-tetrahydropyranyl ethers of19-hydroxy-androst-4-en-3-one and 19-acetoxy-androst-4-en-3-one,respectively. The reference teaches their usefulness as intermediates inthe synthesis of 17β-hydroxyandrost-4-ene-3,19-dione. However, noindication of the utility for these compounds is given other than aschemical intermediates in the reference.

Hormones are generally recognized as being of significance in thebiochemical regulation of the psyche and sexual behavior, Hubble,Lancet, August 3, 1963, 209-214. The aromatization and conversion ofdiverse androgens to estrogen is reported to be responsible for theinduction of estrous behavior in the female of certain non-primatespecies such as the rabbit, Beyer et. al., Endocrinology, 87, 1386-1389(1970). It is also known that estrogen does not form theendocrinological basis for sexual drive in either the male or the femaleprimate, Everitt et. al., Physiology and Behavior 8, 409-415 (1972).Accordingly, it would appear that androgens which are capable ofaromatization to estrogen would be ineffective in the primate.

In contradistinction thereto, applicants have surprisingly discovered auseful class of androst-4-en-19-ols, comprising both new and somepreviously reported compounds, which is capable of being aromatized toestrogen. These compounds are highly effective in enhancing the libidoof both male and female primates, as well as in improving relatedpsychic attitudes associated therewith. Furthermore, these compounds canbe used without obtaining any concomitant, overt, androgenic, somaticside-effects, a result not previously achieved.

SUMMARY OF THE INVENTION

This invention relates to new derivatives of androst-4-en-19-ol, totheir preparation and use as pharmaceutical agents. More particularly,the novel compounds of this invention are represented by the generalformula: ##STR1## wherein R₁ is selected from the group consisting ofH₂, oxo and H(OR₂) with the proviso that when R₆, R₇, R₈ and R₉ are allhydrogen and R₁ is H₂ or oxo and R₂ is hydrogen or acyl, then R₄ or R₅must be selected from the group consisting of lower alkyl having from 1to 3 carbon atoms, trialkylsilyl in which the alkyl group has from 1 to5 carbon atoms, triphenylsilyl, 2-tetrahydropyranyl,4-tetrahydropyranyl, 1-cycloalkenyl having from 5 to 7 carbon atoms,1-methoxycycloalkyl and 1-ethoxycycloalkyl in which the cycloalkyl grouphas from 5 to 7 carbon atoms;

R₂, R₄ and R₅ are each selected from the group consisting of hydrogen,acyl having from 1 to 12 carbon atoms, lower alkyl having from 1 to 3carbon atoms, trialkylsilyl in which the alkyl group has from 1 to 5carbon atoms, triphenylsilyl, 2-tetrahydropyranyl, 4-tetrahydropyranyl,1-cycloalkenyl having from 5 to 7 carbon atoms, 1-methoxycycloalkyl and1-ethoxycycloalkyl in which the cycloalkyl group has from 5 to 7 carbonatoms, with the proviso that when R₄ is tetrahydropyranyl and R₆, R₇, R₈and R₉ are all hydrogen, then R₃ and R₅ cannot both be hydrogen and R₁cannot be oxo;

R₃ is selected from the group consisting of hydrogen, lower alkyl havingfrom 1 to 6 carbon atoms, lower alkenyl having from 2 to 6 carbon atomsand lower alkynyl having from 2 to 6 carbon atoms, and R₃ and OR₄ whentaken together is oxo;

R₆, R₇, R₈ and R₉ are hydrogen and methyl with the proviso that when R₁is oxo, R₄ is hydrogen, acyl or when taken together with R₃ is oxo, R₅is hydrogen and R₉ is methyl, then R₆, R₇ and R₈ cannot all be hydrogenat the same time.

This invention also relates to the unexpected and surprising discoverythat the novel compounds described in formula (I) above, in addition tocertain compounds which have been described in the prior art, possessthe property of enhancing a diminished libido as well as enhancingrelated psychic attitudes in man and other primates withoutdemonstrating any overt androgenic or estrogenic response upon thesecondary sex structures. More particularly, the class of compoundswhich possess this novel utility is represented by the general formula:##STR2## wherein P₁ is selected from the group consisting of H₂, oxo andH(OR₂),

P₂, P₄ and P₅ are each selected from the group consisting of hydrogen,acyl having from 1 to 12 carbon atoms, lower alkyl having from 1 to 3carbon atoms, trialkylsilyl in which the alkyl group has from 1 to 5carbon atoms, triphenylsilyl, 2-tetrahydropyranyl, 4-tetrahydropyranyl,1-cycloalkenyl having from 5 to 7 carbon atoms, 1-methoxycycloalkyl and1-ethoxycycloalkyl in which the cycloalkyl group has from 5 to 7 carbonatoms,

P₃ is selected from the group consisting of hydrogen, lower alkyl havingfrom 1 to 6 carbon atoms, lower alkenyl having from 2 to 6 carbon atoms,and lower alkynyl having from 2 to 6 carbon atoms, and P₃ and OP₄ whentaken together is oxo,

P₆, P₇, P₈ and P₉ are hydrogen and methyl.

DETAILED DESCRIPTION OF THE INVENTION

As shown in formula (I) above, the novel compounds of the presentinvention are substituted in the 1, 3, 4, 6, 7, 17 and 19-positions ofthe androst-4-ene nucleus.

The symbol R₁ represents various substituents located at the 3-positionof this nucleus. Suitable substituents include two hydrogen atoms, anoxo group, and either a substituted or an unsubstituted hydroxyl group.The substituted or unsubstituted hydroxyl group, represented by thesymbol H(OR₂), can be present in either its alpha or beta configuration.When the symbol R₂ represents hydrogen, the free alcohol is, of course,delineated. When the symbol R₂ represents acyl, an ester is present atthe 3-position. Finally, when R₂ represents lower alkyl having from 1 to3 carbon atoms, trialkylsilyl in which the alkyl group has from 1 to 5carbon atoms, triphenylsilyl, 2-tetrahydropyranyl, 4-tetrahydropyranyl,1-cycloalkenyl having from 5 to 7 carbon atoms, 1-methoxycycloalkyl and1-ethoxycycloalkyl in which the cycloalkyl group has from 5 to 7 carbonatoms, the 3-ethers are delineated.

The acyl esters present in the 3-position are derived from monobasicalkyl or aralkyl carboxylic acids having from 1 to 12 carbon atoms. Thecarboxylic acids from which these acylates are derived include saturatedand unsaturated aliphatic acids as well as aromatic acids, as forexample, acetic, propionic, butyric, isobutyric, valeric, isovaleric,caproic, caprylic, decanoic, dodecanoic, acrylic, crotonic,cyclobutanecarboxylic, cyclopentanecarboxylic, cyclopentenecarboxylic,cyclohexanecarboxylic, benzoic, toluic, naphthoic, ethylbenzoic,phenylacetic, naphthaleneacetic, phenylvaleric, cinnamic,phenylpropionic, p-propyloxyphenylpropionic and p-butyloxyphenylaceticacid.

The term lower alkyl as used with regard to the ether substitution inthe 3-position refers to groups having from 1 to 3 carbon atoms, as forexample, methyl, ethyl, propyl and isopropyl. Silyl ethers containing atetrasubstituted silicon atom are similarly substituted with three loweralkyl groups having from 1 to 5 carbon atoms. Alternatively, the siliconatom can be substituted with three phenyl radicals. Ethers which arepresent in the 3-position also include unsaturated cycloalkane ethershaving from 5 to 7 carbon atoms in which the unsaturation is present ina position alpha to the ether oxygen as represented by the term1-cycloalkenyl. Illustrative of such groups are the 1-cyclopentenyl,1-cyclohexenyl or 1-cycloheptenyl radicals. The corresponding saturatedcycloalkane ethers are also considered to be within the scope of thisinvention but here the cycloalkane group is further substituted with amethoxy or an ethoxy radical at its point of attachment, i.e., at the1-position of the cycloalkyl ring. Typical of the saturated heterocyclicradicals which are present as ethers in the 3-position are the2-tetrahydropyranyl and the 4-tetrahydropyranyl radicals.

In order to exclude certain prior art compounds from the novel compoundsbeing claimed, a limitation is included as a proviso for R₁ at the3-position. Thus, whenever the 1,4,6 and 7-positions are substitutedwith hydrogen and at the same time the 3-position is substituted withtwo hydrogen atoms, an oxo group, a hydroxyl group or an ester thereof,then the 17β-position and/or the 19-position must be etherified, i.e.,when R₆, R₇, R₈ and R₉ are all hydrogen and R₁ is H₂ or oxo and R₂ ishydrogen or acyl, then R₄ or R₅ must be selected from the groupconsisting of lower alkyl having from 1 to 3 carbon atoms, trialkylsilylin which the alkyl group has from 1 to 5 carbon atoms, triphenylsilyl,2-tetrahydropyranyl, 4-tetrahydropyranyl, 1-cycloalkenyl having from 5to 7 carbon atoms, 1-methoxycycloalkyl and 1-ethoxycycloalkyl in whichthe cycloalkyl group has from 5 to 7 carbon atoms.

Specifically excluded from the scope of the novel compound describedherein are: 17β,19-dihydroxy-androst-4-en-3-one,17α-ethynyl-17β,19-dihydroxy-androst-4-en-3-one,17α-ethyl-17β,19-dihydroxy-androst-4-en-3-one,17α-ethynyl-17β,19-dihydroxy-androst-4-en-3-one 19-acetate,17β,19-dihydroxy-androst-4-en-3-one 17-benzoate,17β,19-dihydroxy-androst-4-en-3-one 17-acetate,17β,19-dihydroxyandrost-4-en-3-one 17-phenylpropionate,17β,19-dihydroxyandrost-4-en-3-one 17-decanoate,19-hydroxy-androst-4-ene-3,17-dione, 19-hydroxy-androst-4-ene-3,17-dioneacetate, androst-4-ene-17β,19-diol, androst-4-ene-17β,19-diol17-acetate, 17α-methyl-androst-4-ene-17β,19-diol,17α-methyl-androst-4-ene-17β,19-diol 17-acetate,androst-4-ene-3β,17β,19-triol, androst-4-ene-3β,17β,19-triol triacetate,and androst-4-ene-3β,17β,19-triol 3,17-diacetate.

The symbols R₂, R₄ and R₅ all represent identical sets of substituentsat the 3, 17β and 19-positions of the androst-4-ene nucleus,respectively. Each can be varied independently of one another. Suitablesubstituents include hydrogen to indicate that they may be mono, di ortri-substituted hydroxyl groups. Additional substituents include an acylester or a lower alkyl, silyl, tetrahydropyranyl, saturated orunsaturated cycloalkyl ether as previously defined in the 3-positionabove.

In order to exclude the 17-(2'-tetrahydropyranyl ether) of17β,19-dihydroxy-androst-4-en-3-one and its 19-acetate, which aredisclosed in the prior art, a proviso limitation is included for R₄ atthe 17β-position. Thus, when the 17β-(2'-tetrahydropyranyl)ether ispresent and the 1, 4, 6 and 7-positions are all hydrogen, then eitherthe 17α or 19-positions must be substituted other than with hydrogen andthe 3-position cannot be a ketone, i.e., when R₄ is 2-tetrahydropyranyland R₆,R₇,R₈ and R₉ are all hydrogen, then R₃ and R₅ cannot both behydrogen and R₁ cannot be oxo.

The symbol R₃ represents the 17α-position and can be either a hydrogenatom or a saturated or unsaturated aliphatic chain having from 1 to 6carbon atoms. Illustrative of such groups are straight or branched chainalkyl radicals, as for example, methyl, ethyl, propyl, isopropyl, butyl,sec-butyl, isoamyl, n-pentyl and n-hexyl. Illustrative of the alkenylgroups which can be present are the vinyl, allyl, 1-butenyl, 1-pentenyland 1-hexenyl radicals. Illustrative of the alkynyl groups which may bepresent are the ethynyl, 1-propynyl and 1-butynyl radicals. It should benoted that the symbols R₃ and OR₄ when taken together can also representan oxo radical, thereby forming a class of19-(substituted)hydroxy-androst-4-en-17-ones.

The remaining symbols R₆, R₇, R₈ and R₉ each represent hydrogen ormethyl. In order to exclude the compounds19-hydroxy-7α-methyl-androst-4-ene-3,17-dione,17β,19-dihydroxy-7α-methyl-androst-4-en-3-one and17β,19-dihydroxy-7α-methyl-androst-4-en-3-one 17-acetate, disclosed inthe prior art, a limitation is imposed as a proviso for R₆, R₇ and R₈ atthe 1, 4 and 6-positions of the androst-4-ene nucleus, respectively.Thus, where there is a 19-hydroxy-7α-methyl-androst-4-en-3-one havingeither a ketone, or a hydroxyl group or an acyl group in the17β-position then the 1, 4 and 6-positions cannot all remainunsubstituted, i.e., when R₁ is oxo, R₄ is hydrogen, acyl or when takentogether with R₃ is oxo, R₅ is hydrogen and R₉ is methyl, then R₆, R₇and R₈ cannot all be hydrogen at the same time.

A preferred class of compounds includes the 17β-ethers of19-hydroxy-androst-4-ene-3-one and of androst-4-ene-3β,19-diol. Thesecompounds are delineated where R₁ is oxo or H(OR₂), R₂ is hydrogen, R₅is hydrogen and R₄ is an ether moiety previously described with theexception of the 2-tetrahydropyranyl radical. Illustrative of thespecies encompassed within this preferred class of compounds are thecompounds: 19-hydroxy-17β-methoxy-androst-4-en-3-one,19-hydroxy-17β-trimethylsiloxy-androst-4-en-3-one,19-hydroxy-17β-triphenylsiloxy-androst-4-en-3-one,19-hydroxy-17β-(4'-tetrahydropyranyloxy)androst-4-en-3-one,17β-(1'-cyclopentenyloxy)-19-hydroxy-androst-4-en-3-one,17β-(1'-ethoxycyclohexyloxy)-19-hydroxy-androst-4-en-3-one,17β-propoxy-androst-4-ene-3β,19-diol,17β-tributylsiloxy-androst-4-ene-3β,19-diol,17β-triphenylsiloxyandrost-4-ene-3β,19-diol,17β-(4'-tetrahydropryanyloxy)-androst-4-ene-3β,19-diol,17β-(1'-cyclohexenyloxy)-androst- 4-ene-3β,19-diol, and17β-(1'-methoxycyclopentyloxy)androst-4-ene-3β,19-diol.

Another preferred group of compounds are the 19-ethers of androst-4-enein which both the 3 and 17-positions of the steroid nucleus aresubstituted with a hydroxyl and/or an oxo group. Such compounds aredelineated when R₁ is oxo or H(OR₂), R₂ is hydrogen, R₄ is hydrogen orwhen taken together with R₃ is oxo and R₅ includes the various ethersubstituents previously described. Illustrative compounds encompassedwithin this preferred group of 3,17-disubstituted androst-4-en-19-olethers are: 17β-hydroxy-19-methoxy-17α-methyl-androst-4-en-3-one,17α-ethynyl-17β-hydroxy-19-triethylsiloxy-androst-4-en-3-one,17β-hydroxy-17α-propyl-19-(2'-tetrahydropyranyloxy)androst-4-en-3-one,17α-(1'-butynyl)-19-(1'-cyclopentenyloxy)-17β-hydroxy-androst-4-en-3-one,17β-hydroxy-19-(1'-methoxycyclopentyloxy)androst-4-en-3-one,3β-hydroxy-19-propoxyandrost-4-en-17-one,3β-hydroxy-19-triphenylsiloxy-androst-4-en-17-one,3β-hydroxy-19-(4'-tetrahydropyranyloxy)androst-4-en-17-one,19-(1'-cyclohexenyloxy)-3β-hydroxyandrost-4-en-17-one,19-(1'-ethoxycyclopentyloxy)-3β-hydroxy-androst-4-en-17-one,19-ethoxy-androst-4-ene-3,17-dione,19-trimethylsiloxy-androst-4-ene-3,17-dione,19-(2'-tetrahydropyranyloxy)androst-4-ene-3,17-dione,19-(1'-cycloheptenyloxy)androst-4-ene-3,17-dione,19-(1'-methoxycyclohexyloxy)androst-4-ene-3,17-dione,17α-butyl-19-methoxy-androst- 4-ene-3β,17β-diol,17α-ethynyl-19-triphenylsiloxy-androst-4-ene-3β,17β-diol,19-(4'-tetrahydropyranyloxy)androst-4-ene-3β,17β-diol,19-(1'-cyclopentenyloxy)-17α-(1'-pentenyl)androst-4-ene-3β,17.beta.-dioland17α-ethyl-19-(1'-methoxycycloheptyloxy)androst-4-ene-3β,17.beta.-diol.

The final preferred group of compounds are the 17β,19-diethers ofandrost-4-en-3-ol and androst-4-en-3-one. The compounds are delineatedwhen R₄ and R₅ are each selected from the various ether substituentspreviously described, and R₁ is oxo or H(OR₂), R₂ is hydrogen.Illustrative compounds encompassed within this group are:17β-ethoxy-19-triethylsiloxy-androst-4-en-3β-ol,17α-hexyl-17β,19-diisopropoxy-androst-4-en-3β-ol,17α-ethynyl-17β,19-di(triphenylsiloxy)androst-4-en-3β-ol,17α-(1'-butenyl)-17β-(1'-cyclopentenyloxy)-19-ethoxy-androst-4-en-3β-ol,17α-ethyl-17β,19-di(2'-tetrahydropyranyloxy)androst-4-en-3.beta.-ol,19-(1'-ethoxycyclohexyloxy)-17β-pentoxy-17α-(1'-propynyl)androst-4-en-3β-ol,17β-(1'-methoxycycloheptyloxy)-17α-methyl-19-(4'-tetrahydropyranyloxy)androst-4-en-3β-ol,19-methoxy-17β-trimethylsiloxy-androst-4-en-3-one,17β,19-diethoxy-17α-ethyl-androst-4-en-3-one,17α-(1'-butenyl)-17β,19-di(trimethylsiloxy)androst-4-en-3-one,19-(1'-cyclohexenyloxy)-17β-isopropoxy-androst-4-en-3-one,17β,19-di(4'-tetrahydropyranyloxy)androst-4-en-3-one,19-methoxy-17β-(1'-methoxycyclopentyloxy)-17α-(1'-propynyl)androst-4-en-3-one,17α-butyl-19-(1'-ethoxycycloheptyloxy)-17β-triphenylsiloxy-androst-4-en-3-one.

The novel alkyl ethers are prepared from their corresponding hydroxysteroids by reaction with an alkylating agent such as trimethyloxoniumfluoroborate, triethyloxonium fluoroborate or methylfluorosulfonate inan inert chlorocarbon solvent such as methylene chloride. Alternatively,alkylating agents such as alkyl halides, alkyl tosylates, alkylmesylates and dialkylsulfate may be used with a base such as silveroxide or barium oxide in polar, aprotic solvents as for example,dimethylformamide, dimethyl sulfoxide and hexamethylphosphoramide. Thehydroxyl groups can be silylated by reaction with silylating agents suchas trialkylchlorosilane, triarylchlorosilane, N-trialkylsilylacetamidein the presence of an amine base such as triethylamine or pyridine toprepare the novel silyl ethers.

The 2-tetrahydropyranyl ethers are prepared from the correspondinghydroxy steroids by reaction with dihydropyran in the presence of anacid catalyst, as for example, hydrochloric acid, p-toluenesulfonic acidor phosphorous oxychloride.

The 4-tetrahydropyranyl ethers are prepared by reacting the hydroxysteroid, 4-bromotetrahydropyran and a base such as sodium hydridetogether in a polar aprotic solvent such as dimethylformamide,dimethylsulfoxide or hexamethylphosphoramide.

The 1-alkoxycycloalkoxy derivatives are prepared by reacting the hydroxysteroids with a loweralkylketal of a cycloalkanone or the loweralkylenol ether of a cycloalkanone or mixture of these reagents in thepresence of an acidic catalyst such as p-toluenesulfonic acid, pyridinehydrochloride, pyridine p-toluenesulfonate. The reaction is generallyconducted in a solvent such as dioxane, methylene chloride, ether ort-butanol at a temperature less than 70° C., and preferably at 25° C.The preparation of suitable cycloalkyl derivatives is achieved usingsuch reagents as cyclopentanone diethylketal, cyclohexanonedimethylketal, 1-methoxy-1-cyclopentene or 1-ethoxy-1-cyclohexene.Following essentially the same procedure, the 1-cycloalkenyl ethers areprepared directly using, however, higher boiling solvents so that thereaction temperature is above 70° C. Suitable solvents include benzene,toluene and dimethylformamide. Alternatively, the 1-cycloalkenyletherscan be prepared via a pyrolysis of the isolated1-alkoxycycloalkoxysteroid in the presence of a trace of an organic basesuch as pyridine utilizing a high boiling solvent such as benzene ordimethylformamide.

The 3-deoxy-19-substituted androstanes are readily prepared byconversion of the 3-ketone to the 3-ethylenethioketal, followed by Raneynickel desulfurization. Thus, 7α-methyl-4-androsten-17β,19-diol and6α-methyl-4-androsten-17β,19-diol dipropionate are readily prepared inthis manner from 17β,19-dihydroxy-7α-methyl-4-androsten-3-one and17β,19-dihydroxy-6α-methyl-4-androsten-3-one dipropionate, respectively.

Reduction of the androst-4-en-3-ones with metal hydrides such as lithiumaluminum hydride, lithium tri-t-butoxyaluminum hydride and sodiumborohydride produces the corresponding 3β-alcohol. The use of a highlyhindered lithium or potassium trialkylborohydride such as potassiumtri-sec-butylborohydride results in the formation of the axial alcohol,namely, the androst-4-en-3α-ol.

The reaction of dichlorodicyanobenzoquinone with19-hydroxy-4-androsten-3-ones in refluxing dioxane or methylenechloridefor 24-72 hours produces the corresponding19-hydroxy-1,4-androstadien-3-one. However, two restrictions in thissequence are necessary. First, the 19-hydroxy group must be protected asan ester or ether in order to avoid aromatization. Secondly, the1-position must possess an axial hydrogen atom for elimination. Thus,the 1α-methyl androstene is not reactive although the 1β-methylandrostane is. Following this procedure17β,19-dihydroxy-7α-methyl-4-androsten-3-one dipropionate is convertedto 17β,19-dihydroxy-7α-methyl-1,4-androstadien-3-one dipropionate.Similarly, 19-hydroxy-6α-methyl-4-androsten-3,17-dione acetate forms19-hydroxy-6α-methyl-1,4androstadien-3,17-dione acetate and1β-methyl-19-tetrahydropyranyloxy-4-androsten-3,17-dione forms1-methyl-19-tetrahydropyranyloxy-1,4-androstadien-3,17-dione.

The 1α-methyl-19-substituted-androst-4-enes are produced by reacting thecorresponding androsta-1,4-dien-3-ones with dimethyllithium copper.Methylation is preferably conducted by adding theandrosta-1,4-dien-3-one dissolved in an inert solvent, to a solution ofdimethyllithium copper in the same or a different inert solvent.Suitable inert reaction solvents include methylene chloride,tetrahydrofuran, dioxane, hexane, benzene with diethyl ether being thesolvent preferred. The reaction is conducted at temperatures between-75° C. and 20° C. with a temperature range of from about -5° C. to 0°C. being preferred. The ratio of reactants is not critical, but at least2 molar equivalents of dimethyllithium copper must be present for eachconjugate addition. The presence of free hydroxyl groups will, ofcourse, require additional equivalent amounts of the organometallicreagent. Following this procedure,19-hydroxy-androst-1,4-diene-3,17-dione propionate can be converted to19-hydroxy-1α-methylandrost-4-en-3,17-dione propionate.

The 1β-methyl-19-substituted-4-androst-3-ones are synthesized in themanner of Simmons and Smith by treatment of a19-substituted-androsta-1,5-diene-3β-ol with methylenediiodide and azinc-copper couple to form the19-substituted-1β,2β-methylene-androst-5-ene-3β-ol. The presence of the3β-alcohol as well as the 19-alcohol direct the insertion to the betaside. The 1β,2β-methylene-3β-ol is then oxidized to a 3-one and thecyclopropyl ring cleaved by acid or base to form the19-substituted-1β-methyl-4-androsten-3-one. Typically a mixture ofzinc-copper couple, iodine and methylenediiodide in an inert solventsuch as diethylether, tetrahydrofuran, dioxane or diglyme is heated withan infrared lamp for thirty minutes. The steroid, also in an inertsolvent as above, is added and the mixture heated from 25° to 100° for30 minutes to 72 hours. Generally, reflux temperatures of the solventemployed combined with a 24 hour reflux period is sufficient. TheSimmons-Smith reagent is taken in 5-10 fold excess. The oxidation of the3-alcohol is readily achieved with various oxidizing agents.Illustrative oxidizing agents are Jones reagent, CrO₃.pyridine complex(Sarett reagent), and Cornforth reagent. However, if the 19-alcohol isnot suitably protected, it also will be oxidized. The remaining1β,2β-methylene ring is then cleaved to the 1β -methyl group byrefluxing with zinc in acetic acid. In this manner19-tetrahydropyranyloxy-1,5-androstadien-3,17-diol is converted to1β-methyl-19-hydroxy-4-androstene-3,17-dione.

Methylation of 19-hydroxy-4-androsten-3-ones using Atwater's procedure(N.W. Atwater, J. Am. Chem. Soc. 79, 5315 (1957)) of addingmethylchloride slowly to a refluxing solution of the ketone in t-butanolcontaining only a small excess of potassium t-butoxide produces the19-hydroxy-4-methyl-4-androsten-3-ones in fair yield. Following thisprocedure 19-hydroxy-7α-methyl-androst-4-ene-3,17-dione and17β,19-hydroxy-1α,7α-dimethyl-androst-4-en-3-one can be converted to19-hydroxy-4,7α-dimethyl-androst-4-ene-3,17-dione and17β,19-dihydroxy-1α,4,7α-trimethylandrost-4-en-3-one, respectively.

Alternatively, the 19-hydroxy-4-androsten-3-one can be selectivelythiomethylated at position 4 with formaldehyde and a thiol under basicconditions. Benzylmercaptan is the preferred thiol. Desulphurisation ofthe intermediate 19-hydroxy-4-phenylthiomethyl-4-androsten-3-one leadsto the monomethylated 19-hydroxy-4-methyl-4-androsten-3-one in goodyield.

Treatment of a 5α,6α-epoxyandrostane-3,19-diol or a3,3-ethylenedioxy-5α,6α-epoxyandrostan-19-ol with methylmagnesiumbromide in dry solvents such as diethyl ether, tetrahydrofuran, benzeneor toluene at temperatures between 0° C. to 100° C., results in epoxidecleavage to give the corresponding 6β-methyl-androstane-5α,19-diols. Thecorresponding 3-alcohol can be oxidized or the ketal group hydrolysedwith hot acetic acid or dilute aqueous methanolic mineral acid to formthe 5α-hydroxy-6β-methyl-3-ketone. Dehydration of the β-hydroxy ketonewith sodium hydroxide in hot aqueous methanol is accompanied byinversion at 6 to form the 6α-methylandrost-4-en-3-one. In this mannerthe compounds 17β,19-dihydroxy-6α-methyl-4-androsten-3-one,17β-hydroxy-6α,17α-dimethyl-4-androstene-3,19-dione are preparedstarting with 3,3-ethylenedioxy-5α,6α-epoxyandrostan-17,19-diol and5α,6α-epoxy-17α-methylandrostan-3β,17β,19-diol, respectively.

The 7α-methyl-4-androstene-3,19-diones are produced by alkylating thecorresponding 4,6-androstadiene-3,19-dione with dimethyllithium copperin an inert solvent such as diethyl ether, tetrahydrofuran, hexane ormixtures of these at temperatures ranging from -78° C. to 25° C.Tetrahydrofuran is the preferred solvent and temperatures between -5° C.to 10° C. provide optimum results. Quenching the initially formedenolate anion with a weak protonating agent such as a saturated solutionof ammonium chloride, oxalic acid or boric acid provides the7α-methyl-5-androstene-3,19-diones. Quenching the enolate with a strongprotonating agent such as hydrochloric acid provides the7α-methyl-4-androstene-3,19-diones.

The 7α-methyl-4-androstene-3,19-dione can also be prepared by eitheracid or base catalyzed isomerization of the corresponding7α-methyl-5-androstene-3,19-dione. Suitable acid catalysts includehydrochloric acid, sulfuric acid p-toluenensulfonic acid and acetic andthey can be used in such solvents as methanol, ethanol, dioxane,tetrahydrofuran and methylenechloride. Suitable base catalysts for thisisomerization include sodium hydroxide or sodium methoxide in an alcoholsolvent such as methanol.

Following this procedure 1α,7α-dimethyl-4-androstene-3,17,19-trione,7α-methyl-17β-(2'-tetrahydropyranyloxy)-4-androstene-3,19-dione and17β-hydroxy-7α,17α-dimethyl-4-androstene-3,19-dione are preparedstarting with 1α-methyl-4,6-androstadiene-3,17,19-trione,17β-(2'-tetrahydropyranyloxy)-4,6-androstadiene-3,19-dione and17β-hydroxy-4,6-androstadiene-3,19-dione. These7α-methyl-4-androstene-3,19-diones can be reduced to the diols withreagents such as lithium aluminum hydride, lithiumtri-t-butoxyaluminumhydride, sodium borohydride or potassiumborohydride. The 3-hydroxyl group can then be selectively oxidized withreagents specific for allylic alcohol oxidation such as activatedmanganese dioxide or dichlorodicyanobenzoquinone. Following thisprocedure the 19-hydroxy-4-androsten-3-one is prepared. Morespecifically, 1α,7α-dimethyl-14-androstene-3,17,19-trione can beconverted to 1α,7α-dimethyl-4-androstene-3β,17β,19-triol and17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one. Similarly,7α-methyl-17β-(2'-tetrahydropyranyloxy)-4-androstene-3,19-dione can beconverted to7α-methyl-17β-(2'-tetrahydropyranyloxy)-4-androstene-3β,19-diol and19-hydroxy-7α-methyl-17β-(2'-tetrahydropyranyloxy)-4-androsten-3-one.

The 19-hydroxy-androst-4-en-3-ones used in the present invention are,broadly speaking, prepared by the methods described in Vol. II ofOrganic Reactions in Steroid Chemistry, Edited by J. Fried and J. A.Edwards, p. 237-87; van Nostran Reinhold Company, N.Y., (1972). Oneroute to the 19-hydroxyandrost-4-en-3-ones proceeds from the5α-halogen-6β,19-ether intermediates. These compounds are prepared fromthe corresponding 5,6-unsaturated steroids by the addition of ahypohalous acid forming the 5α-halogen-6β-carbinols, which aresubsequently cyclized by means of lead tetraacetate or by decompositionof the 6β-hypohalites to yield the desired 5α-halogen-6β,19-ethers.Thus, for example, 3β,17β-dihydroxy-5-androstene diacetate is convertedto 5α-bromo-3β,6β,17β-trihydroxyandrostane 3,17-diacetate by means ofhypobromous acid. Lead tetraacetate or hypoiodide converts this to5α-bromo-3β,17β-dihydroxy-6β,19-oxidoandrostane 3,17-diacetate.Likewise, 3β-hydroxyandrost-5-en-17-one acetate is converted to5α-chloro-3β,6β-dihydroxyandrostan-17-one 3-acetate by means ofhypochlorous acid. A lead tetraacetate or hypoiodite oxidation convertsthis latter compound into5α-chloro-3β-hydroxy-6β,19-oxidoandrostane-17-one acetate. This17-ketone reacts with an organometallic reagent such as methylmagnesiumbromide or lithium acetylide to form the desired 17α-alkylated17β-hydroxy derivative.

The 3-oxo-4-ene group is next introduced by oxidizing the3β-hydroxy-5α-halo-6β,19-oxide intermediate with an oxidizing reagentsuch as chromium trioxide. Subsequent dehydrohalogenation using pyridineor sodium acetate in methanol results in the formation of thecorresponding 6β,19-oxidoandrost-4-en-3-one. This 6β,19-ether isreductively cleaved using reagents such as zinc and isopropanol, zincand acetic acid or lithium and ammonia to form the desired19-hydroxyandrost-4-en-3-one. In addition to providing the19-hydroxyandrostane starting materials for either introduction ofmethyl groups at 1,4,6,7 either singly or in combinations, this reactionsequence can be carried out with the methyl groups in these positionsalready present to produce the compounds of this invention directly.

An alternative route to the 19-hydroxyandrost-4-en-3-ones proceeds fromthe 6β,19-oxido-3α,5α-cycloandrostanes as intermediates. These compoundsare in turn prepared by a lead tetraacetate or hypoiodite oxidation uponthe corresponding 6β-hydroxy-3α,5αcycloandrostane, an i-steroid. Heatingthe 6β,19-ether in a solvent such as dimethylsulfoxide withbenzoylperoxide results in cleavage and the direct formation of the19-hydroxyandrost-4-en-3-one. Alternatively, the 6β,19 ether can becleaved to the corresponding 3β,19-dihydroxy-5-androstene using sulfuricacid in an aqueous acetone solution. This compound is then oxidized tothe desired 19-hydroxyandrost-4-en-3-one by means of an Oppenaueroxidation.

The novel 3,17 and 19 ethers of this invention are selectively preparedby protection of the hydroxy groups, by selective oxidation or selectivereduction sequences. The compound 19-hydroxy-androst-4-ene-3,17-dione isetherified in the manner previously described to produce the 19-OR₁derivatives of androst-4-ene-3,17-dione. Reduction of these ketones withlithium aluminum hydride, lithium trialkoxyaluminum hydride or sodiumborohydride results in the formation of the corresponding 3,17-dihydroxyanalogues. Thus, for example,19-trimethylsiloxyandrost-4-ene-3,17-dione,19-tetrahydropyranyloxyandrost-4-ene-3,17-dione,19-methoxyandrost-4-ene-3,17-dione are converted by the above procedureto 19-trimethylsiloxyandrost-4-en-3β,17β-diol,19-tetrahydropyranyloxyandrost-4-ene-3β,17β-diol and19-methoxyandrost-4-ene-3β,17β-diol respectively.

The compound 17β,19-dihydroxyandrost-4-en-3-one is similarly etherifiedto form the 17β-OR₄, 19-OR₁, derivatives of androst-4-en-3-one.Reduction as previously described yields the corresponding 3-hydroxyanalogues. For example, 17β,19-dihydroxyandrost-4-en-3-one is convertedto 17β,19-di-triphenylsiloxyandrost-4-en-3-one and17β,19-di-(1-methoxy-1-cyclopentyloxy)-androst-4-en-3-one as previouslydescribed. These compounds are then reduced using lithium aluminumhydride in an ether or tetrahydrofuran solution to produce17β,19-di-triphenylsiloxyandrost-4-en-3β-ol and17β,19-di-(1-methoxy-1-cyclopentyloxy)-androst-4-en-3β-ol, respectively.

The 3,17,19-triethers are readily available fromandrost-4-ene-3β,17β,19-triol in the manner presented earlier. The3,17-diethers are also available. For example,19-hydroxyandrost-4-ene-3,17-dione is acetylated in the usual mannerwith acetic anhydride and pyridine to form the corresponding 19-acetate.The 3,17-diketones are then selectively reduced using lithiumtri-t-butoxy aluminum hydride to give androst-4-ene-3β,17β,19-triol19-acetate. Etherification of positions 3 and 17 in the aforementionedmanner results in the preparation, for example, of3β,17β-(1-cyclopentenyloxy)-androst-4-en-19-ol acetate or3β,17β-ditetrahydropyranyloxyandrost-4-en-19-ol acetate. Cleavage ofthese 19-acetates with lithium aluminum hydride results in the formationof 3β,17β-(1-cyclopentenyloxy)-androst-4-en-19-ol and3β,17β-ditetrahydropyranyloxyandrost-4-en-19-ol, respectively.

Acyl groups are introduced by standard methods known to those skilled inthe art such as the reaction with an acid anhydride or chloride in thepresence of an alkaline component such as pyridine. Mixed ether/estersare prepared by suitable combinations of these general methods. Forexample, 17β,19-dihydroxyandrost-4-en-3-one can be acetylated to formthe diacetate. The remaining 3-ketone is reduced to the correspondingalcohol and etherified to yield a 3-ether-17,19-diacetate. Cleavage ofthe 17,19-diacetate to the corresponding alcohols as previouslydescribed results in the preparation, for example, of3β-methoxy-androst-4-ene-17β,19-diol and3β-(1-ethoxycyclohexyloxy)-androst-4-ene-17β,19-diol, respectively.

A 17β,19-dihydroxy-4-androsten-3-one diester can be selectivelyhydrolyzed to the 17-monoester by refluxing one hour in 10% aqueousmethanol containing one equivalent sodium bicarbonate. In this manner17β,19-dihydroxy-4-methyl-4-androsten-3-one dipropionate and17β,19-dihydroxy-4-androsten-3-one diacetate are converted to17β,19-dihydroxy-4-methyl-4-androsten-3-one 17-propionate and17β,19-dihydroxy-4-androsten-3-one 17-acetate, respectively.

A 19-hydroxy-4-androstene-3,17-dione can be selectively reduced to17β,19-dihydroxy-4-androsten-3-one by the action of potassiumborohydride in ethanol at -10° to 0° C. for reaction periods of lessthan 5 hours. In this manner6α-methyl-19-(2'-tetrahydropyranyloxy)-4-androstene-3,17-dione and19-ethoxy-1α-methyl-4-androstene-3,17-dione can be selectively reducedto 17β-hydroxy-6α-methyl-19-(2'-tetrahydropyranyloxy)-4-androsten-3-oneand 19-ethoxy-17β-hydroxy-1α-methyl-4-androsten-3-one, respectively.

A 4-androstene-3β,17β,19-triol can be selectively oxidized to a17β,19-dihydroxy-4-androsten-3-one by activated manganese dioxide in aninert solvent such as methylene chloride or chloroform at temperaturesbelow 25° C. Elevated temperatures promote oxidation at position 19.This selective allylic oxidation is also accomplished by the action ofdichlorocyanobenzoquinone on the triol in solvents such as dioxane ormethylenechloride. The preferred temperature is below 25° C. and typicalreaction times range from about 1 to about 18 hours. With these reagents1β-methyl-4-androstene-3β,17β,19-triol and17α-ethinyl-4-androstene-3β,17β,19-triol are converted to17β,19-dihydroxy-1β-methyl-4-androsten-3-one and17α-ethinyl-17β,19-dihydroxy-4-androsten-3-one, respectively.

The novel compounds of this invention, represented by formula (I), areuseful in modulating the behavior of normal, non-hostile animals whenplaced in contact with hostile aggressive animals. Hostile aggression inanimals can be induced by prolonged isolation of individual animals inthe dark. Modulation of the behavioral response in the treated, normallynon-hostile animals towards the aggressive animals broadly suggeststheir use in humans for certain psychasthenic syndromes and relatedconditions of mental health.

Applicants have made the further important discovery that the19-hydroxy-androst-4-enes described in formula (II) above, possess theremarkable ability of enhancing libido and related psychic attitudes inman and other primates. Additionally they generally improve the sense ofmental and emotional well-being in primates as well as increase theability to perform repetitive mental tasks. In striking contrast to theandrogens previously used for this purpose, these beneficial effects areachieved without any overt concomitant androgenic side-effects upon thesex accessory structures.

The expression "libido" as used herein refers to those aspects of thehuman and primate psyche which are related to sexual interest and drive.Additionally, the expression "libido" refers to related psychicattitudes concerned with mental well-being and which refer to suchcharacteristics as mental alertness and activity, creativity,enthusiasm, sociability and an awareness of interpersonal relationships.Libido is generally recognized to be the result of a complex interactionof factors in which genetic, anatomic, neurologic, psychologic andbiochemical factors all play prominent roles. The exact mechanism bywhich the compounds of the present invention achieve this effect is notunderstood except to the extent that it is attributable to a biochemicalmechanism.

Secretions of the endocrine glands are known to affect the psyche. Thus,there is a degree of positive correlation between testosterone bloodlevel changes and dominant or aggressive behavior. Testosterone infusionis also known to improve mental performance in repetitive mental tasks.It has recently been suggested that a dysgenesis of androgen steroidsmay have a bearing in schizophrenia, cf., Alias, A. G., Lancet, 1248-9,No. 2 (1972).

The fact that libido in both men and women bears a relationship to theendocrine system, and more particularly, to the steroidal hormonesassociated therewith, has also been previously reported, and isclinically recognized. Physicians are often confronted with patientshaving a variety of symptoms including those of a diminished libido andrelated psychasthenia, which may be either organic or psychosomatic inorigin. Heretofore, therapy employing the administration of testosteroneand its esters, or the orally active 17-methyltestosterone hasfrequently been employed. Adjunctive androgen therapy is alsorecommended for the restoration of libido in women with certaingynecologic disturbances and in women who have had oophorectomy andbilateral adrenalectomy. Similarly, androgen therapy has been used torestore libido in impotent men whose impotence has been associated withan endocrine malfunction or insufficiency, as for example, in Addison'sdisease, castration, diabetes mellitus, eunuchoidism, feminizinginterstitial-cell tumors, infantilism and obesity.

Although in some patients such treatment has been effective, it hasgenerally proven to be disappointing due to the physiological sideeffects of the androgen which soon become apparent. In the female,therapeutic doses of testosterone can produce a virilizing effectincluding hirsuitism, hoarseness or deepening of the voice and anincrease in uterine weight. In the male such symptoms as an increasedgrowth of body hair, an increase in weight of the ventral prostate,enlarged seminal vesicles, increased seminal fluid and sterility havebeen observed.

The castrated rhesus monkey is a useful primate model in which todemonstrate and observe enhanced libidinous behavior. However, the sizeand temperament of these animals, plus the expense of maintaining largemonkey colonies, makes them unsuitable for ordinary routine screening oflarge numbers of compounds. The castrated or thecastrated-adrenalectomized rat is a more practicable and manageableanimal model that can be accommodated in the large numbers required forthe successful testing of compounds, and are the standard experimentalanimals employed for the evaluation of chemical compounds by thoseskilled in the art. Furthermore, a high degree of correlation exists inthe data obtained using the castrated rat and the castrated monkey.

When administered to castrated or castrated-adrenalectomized rats the19-hydroxy-androst-4-enes described herein result in both an increase inthe number and frequency of mounts, intromissions and ejaculations ascompared with castrated control animals. Additionally, there is observeda decrease in the refractory period following emission. This refractoryor post-ejaculatory period for the rat refers to the time periodfollowing emission and prior to remounting. During this period the malerat is sexually inert and will even resist any sexual advances made bythe female. Many observers feel the refractory period provides a morerealistic evaluation of libido enhancement. On necropsy of the animalstreated, examinations of the secondary sex organs, i.e., the ventralprostate and seminal vesicles, fail to show any overt, peripheral,somatic effects normally associated with androgen administration, andmore particularly associated with the administration of testosterone.

The compounds of the present invention can be administered in variousunit dosage forms including tablets or lozenges for purposes ofabsorption through the buccal mucosa. The active ingredient may beenclosed in hard or solf gelatin capsules, or it may be compresseddirectly into tablets, or they may be incorporated with otherpharmaceutical excipients and inert diluents and used in the form oftroches, elixirs, suspensions, syrups, wafers, chewing gum and the like.Such compositions and preparations can contain anywhere from 0.1milligram to about 3 grams of active compound per dosage unit form.Preferably an amount of active ingredient ranging from 0.1 milligram to500 milligrams is employed per dosage unit. The tablets, troches, pillsand capsules may also contain the following pharmaceutical excipients: abinder such as gum tragacanth, acacia, corn starch or gelatin; a diluentsuch as dicalcium phosphate; a disintegrating agent such as corn starch,potato starch, alginic acid; a lubricant such as magnesium stearate; asweetening agent such as sucrose, lactose or saccharin, and flavoringagents such as peppermint, oil of wintergreen or cherry flavoring.Various other materials may also be present as coatings or to otherwisemodify the physical form of the dosage unit, as for example,shellac-coated tablets or capsules and sugar-coated tablets. Syrups orelixirs may contain the active ingredients, sucrose as a sweeteningagent, methyl and propyl parabens as preservatives, and a suitable dyeor flavoring agent.

Parenteral fluid dosage forms or injectable forms including those whichcan be administered by a jet gun are prepared by utilizing the activeingredient in a sterile liquid vehicle such as water or saline solution.Compositions having the desired clarity, stability and adaptability forparenteral use are obtained by dissolving from about 0.1 milligram toabout 3 grams of the active ingredient in a vehicle consisting of amixture of nonvolatile, liquid polyethylene glycols which are soluble inwater and organic liquids and which have molecular weights ranging fromabout 200 to about 1,500. Such solutions may advantageously containsuspending agents, such as sodium carboxymethylcellulose,methylcellulose, polyvinyl pyrrolidone or polyvinyl alcohol. In the caseof injectable forms, they may also contain preservatives in the natureof bactericidal and fungicidal agents, as for example, parabens, benzylalcohol, phenol or thimerosal. If desired, isotonic agents are includedsuch as various sugar or sodium chloride. Adjuvants include localanesthetics and stabiliing or buffering agents may also be usefullyemployed.

The active ingredient can also be compressed into pellets or smallcylinders and implanted subcutaneously or intramuscularly as depotinjections or implants. Implants may employ inert materials such asbiodegradable polymers or synthetic silicones, as for example, Silastic,silicone rubber manufactured by the Dow-Corning Corporation.Implantation results in a slow but, nevertheless, predictable rate ofabsorption from the site of implantation.

The following preparations and examples are illustrative of the novelcompounds of the present invention and their compositions but are not tobe construed as necessarily limiting the scope thereof.

EXAMPLE 1 19-(Trimethylsiloxy)-4-androstene-3,17-dione

A mixture of 9.0 gm (0.03 mole) of 19-hydroxy-4-androstene-3,17-dione,4.3 gm (0.04 mole) of trimethylchlorosilane and 3.2 gm (0.04 mole) ofpyridine is refluxed in 100 ml of benzene for a period of 18 hours. Theresulting suspension is filtered, the volatiles removed in vacuo andconcentrated to a yellow oil. The oil is placed upon a silica gelchromatographic column packed in chloroform and eluted with chloroform.The chloroform eluate is evaporated to dryness in vacuo and the residueis recrystallized twice from hexane to yield the desired19-(trimethylsiloxy)-4-androstene-3,17-dione having a m.p. of 87°-9° C.,uv max (MeOH) 242 nm (ε14,700).

Following essentially the same procedure but substitutingtriethylchlorosilane and tripropylchlorosilane for thetrimethylchlorosilane above results in the formation of19-(triethylsiloxy)-4-androstene-3,17-dione and19-(tripropylsiloxy)-4-androstene-3,17-dione, respectively.

Substituting 19-hydroxy-1β-methyl-4-androstene-3,17-dione and19-hydroxy-6α-methyl-4-androstene-3,17-dione for the19-hydroxy-4-androstene-3,17-dione above results in the formation of1β-methyl-19-trimethylsiloxy-4-androstene-3,17-dione and6α-methyl-19-trimethylsiloxy-4-androstene-3,17-dione.

EXAMPLE 2 19-(Triphenylsiloxy)-4-androstene-3,17-dione

A solution of 9.0 gm (0.03 mole) of 19-hydroxy-4-androstene-3,17-dione,11.8 gm (0.04 mole) of triphenylchlorosilane and 9.6 gm (0.12 mole) ofpyridine contained in 100 ml of benzene is refluxeed for a period of 18hours. The resulting suspension is filtered and concentrated in vacuo toa yellow oil. The oil is placed on a silica gel chromatographic columnpacked in chloroform which is further eluted with chloroform. Thechloroform eluant is evaporated to dryness in vacuo and recrystallizedfrom methanol to yield 19-(triphenylsiloxy)-4-androstene-3,17-dionemethanolate having a m.p. 100°-2° C., uv max (MeOH) 223 nm (ε30,430),242 nm (ε17,300).

Following essentially the same procedure but substituting19-hydroxhy-1β-methyl-4-androstene-3,17-dione and19-hydroxy-6α-methyl-4-androstene-3,17-dione for the19-hydroxy-4-androstene-3,17-dione above results in the preparation of1β-methyl-19-triphenylsiloxy-4-androstene-3,17-dione and6α-methyl-19-triphenylsilioxy-4-androstene-3,17-dione.

EXAMPLE 3 3β, 17β,19-Tri(trimethylsiloxy)androst-4-ene

Androst-4-ene-3β,17β,19-triol is dissolved in dry pyridine andtrimethylsilyacetamide added thereto. The reaction is completed at roomtemperature within a few minutes. The pyridine is removed under reducedpressure and the residue purified from an acetone-hexane solution toyield the desired 3β,17β,19-tri(trimethylsiloxy)androst-4-ene.

Following essentially the same procedure but substituting1α-methyl-4-androstene-17β,19-diol,1α-methyl-4-androstene-3β,17β,19-triol and7α-methyl-4-androstene-3β,17β,19-triol for theandrost-4-ene-3β,17β,19-triol above results in the formation of1α-methyl-17β,19-di(trimethylsiloxy)androst-4-ene,1α-methyl-3β,17β,19-tri(trimethylsiloxy)androst-4-ene and7α-methyl-3β,17β,19-tri(trimethylsiloxy)-4-androstene, respectively.

EXAMPLE 4 17β,19-Di-(1'-ethoxy-1'-cyclohexyloxy)androst-4-en-3-one

A suspension of 17β,19-dihydroxyandrost-4-en-3-one in anhydrous dioxaneis treated at room temperature with pyridine p-toluenesulfonate andcyclohexanone ethyl enolether. The steroid dissolves and a newprecipitate forms which upon standing overnight is filtered andrecrystallized from methanol-methylene chloride to yield the desired17β,19-di-(1'-ethoxy-1'-cyclohexyloxy)androst-4-en-3-one.

Using essentially the same procedure but substituting17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one and17β,19-dihydroxy-7α-methyl-4-androsten-3-one for the17β,19-dihydroxyandrost-4-en-3-one above results in the preparation of17β,19-di-(1'-ethoxy-1'-cyclohexyloxy)-1α,7α-dimethyl-4-androsten-3-oneand 17β,19-di-(1'-ethoxy-1'-cyclohexyloxy)-7α-methyl-4-androsten-3-one.

EXAMPLE 5 17β,19-Di-(1'-cyclohexenyloxy)androst-4-en-3-one

17β,19-Di-(1'-ethoxy-1'-cyclohexyloxy)androst-4-en-3-one is dissolved indimethylformamide containing a drop of pyridine. The solution is heatedat 150° C. for 1 hour allowing the alcohol which forms to distill out.The solvent is removed under vacuum and the residue recrystallized frommethanol to yield the desired17β,19-di-(1'-cyclohexenyloxy)androst-4-en-3-one.

In essentially the same manner substituting17β,19-di-(1'ethoxy-1'-cycohexyloxy)-1α,7α-dimethyl-4-androsten-3-oneand 17β,19-di-(1'-ethoxy-1'-cyclohexyloxy)-7α-methyl-4-androsten-3-onefor the 17β,19-di-(1'-ethoxy-1'-cyclohexyloxy)androst-4-en-3-one aboveresults in the formation of17β,19-di-(1'-cyclohexenyloxy)-1α,7α-dimethyl-4-androsten-3-one and17β,19-di-(1'-cyclohexenyloxy)-7α-methyl-4-androsten-3-one.

EXAMPLE 6 17β,19-Di-(1'-cyclohexenyloxy)androst-4-en-3β-ol

17β,19-di-(1'-cyclohexenyloxy)androst-4-en-3-one is dissolved inanhydrous ether and added to a suspension of lithium aluminum hydride inanhydrous ether. After stirring for a period of 16 hours, water iscautiously added. The resulting mixture is filtered, dried overmagnesium sulfate and concentrated in vacuo. The residue is crystallizedfrom methanol to yield the desired17β,19-di-(1'-cyclohexenyloxy)androst-4-en-3β-ol.

In the same manner substituting17β,19-di-(1'-cyclohexenyloxy)-1α,7α-dimethyl-4-androsten-3-one and17β,19-di-(1'-cyclohexenyloxy)-7α-methyl-4-androsten-3-one for the17β,19-di-(1'-cyclohexenyloxy)androst-4-en-3-one above, results in thepreparation of17β,19-di-(1'-cyclohexenyloxy)-1α,7α-dimethyl-4-androsten-3β-ol and17β,19-di-(1'-cyclohexenyloxy)-7α-methyl-4-androsten-3β-ol.

EXAMPLE 717α-Methyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one

17β,19-Dihydroxy-17α-methylandrost-4-en-3-one, phosphoryl chloride and2,3-dihydropyran are permitted to stand for a period of 16 hours at roomtemperature. The reaction mixture is diluted with ether, washed with anaqueous sodium carbonate solution, followed by a water wash, dried oversodium sulfate, and evaporated to dryness under vacuum. Crystallizationof the residue from methanol results in the formation of17α-methyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one.

Following essentially the same procedure but substituting17β,19-dihydroxy-4,6α,17α-trimethyl-4-androsten-3-one,17β,19-dihydroxy-4,17α-dimethyl-4-androsten-3-one and17β,19-dihydroxy-6α,17α-dimethyl-4-androsten-3-one for the17β,19-dihydroxy-17α-methylandrost-4-en-3-one above, results in theformation4,6α,17α-trimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one,4,17α-dimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one and6α,17α-dimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one,respectively.

EXAMPLE 817α-Methyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3.beta.-ol

An ether solution of17α-methyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one isadded to a lithium aluminum hydride suspension in ether. After refluxingfor one hour, the excess hydride is cautiously decomposed with water.The ether solution is separated, dried over sodium sulfate andconcentrated under vacuum. The remaining residue is recrystallized frommethanol to yield the desired17α-methyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3.beta.-ol.

Following essentially the same procedure but substituting4,6α,17α-trimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one,4,17α-dimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-one and6α,17α-dimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3-onefor the 17α-methyl-17β,19di-(2'-tetrahydropyranyloxy)androst-4-en-3-oneabove, results in the preparation of4,6α,17α-trimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3β-ol,4,17α-dimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3βol, and6α,17α-dimethyl-17β,19-di-(2'-tetrahydropyranyloxy)androst-4-en-3β-ol,respectively.

EXAMPLE 9 17α-Propynyl-17β,19-di-(trimethylsiloxy)androst-4-en-3-one

17β,19-Dihydroxy-17α-propynyl-androst-4-en-3-one, trimethylchlorosilane,and pyridine are refluxed in toluene for a period of 18 hours. Theresulting suspension is filtered, and the toluene removed under vacuum.The remaining residue is recrystallized from hexane to yield the desired17α-propynyl-17β,19-di-(trimethylsiloxy)androst-4-en-3-one.

Substituting 17β,19-dihydroxy-6α,17α-dimethyl-4-androsten-3-one for the17β,19-dihydroxy-17α-propynylandrost-4-en-3-one above, results in thepreparation of6α,17α-dimethyl-17β,19-di-(trimethylsiloxy)androst-4-en-3-one.

EXAMPLE 10 19-Methoxyandrost-4-ene-3,17-dione

19-Hydroxyandrost-4-ene-3,17-dione is dissolved in methylenechloride andtrimethyloxonium fluoroborate added. After stirring at room temperaturefor a period of two hours, water is added to the reaction mixture, theorganic layer is separated, dried over magnesium sulfate and the solventremoved under vacuum. The residue is crystallized from an acetone-hexanesolution to yield the desired 19-methoxyandrost-4-ene-3,17-dione.

Using essentially the same procedure but substituting19-hydroxy-1β-methyl-4-androstene-3,17-dione and19-hydroxy-6α-methyl-4-androstene-3,17-dione for the19-hydroxyandrost-4-ene-3,17-dione above results in the formation of19-methoxy-1β-methyl-4-androstene-3,17-dione and19-methoxy-6α-methyl-4-androstene-3,17-dione.

EXAMPLE 11 19-Methoxyandrost-4-ene-3β,17β-diol

19-Methoxyandrost-4-ene-3,17-dione is dissolved in methanol and thesolution cooled to 0° C. Sodium borohydride is added over a period offifteen minutes and stirring continued for an additional two hours. Thesolution is poured into water containing a few drops of acetic acid. Thewhite precipitate which forms is collected by filtration, dried andcrystallized from acetone to yield the desired19-methoxy-androst-4-ene-3β,17β-diol.

Substituting 19-methoxy-1β-methyl-4-androstene-3,17-dione and19-methoxy-6α-methyl-4-androstene-3,17-dione results in the preparationof 19-methoxy-1β-methyl-4-androstene-3β,17β-diol and19-methoxy-6α-methyl-4-androstene-3β,17β-diol.

EXAMPLE 12 19-Methoxyandrost-4-ene-3β,17β-diol diacetate

19-Methoxyandrost-4-ene-3β,17β-diol is dissolved in a mixture of aceticanhydride and pyridine and the solution allowed to stand overnight atroom temperature. The solvents are removed under vacuum and theremaining residue crystallized from acetone-hexane to yield19-methoxyandrost-4-ene-3β,17β-diol diacetate.

Substituting 19-methoxy-1β-methyl-4-androstene-3β,17β-diol and19-methoxy-6α-methyl-4-androstene-3β,17β-diol in lieu of the19-methoxyandrost-4-ene-3β,17β-diol above results in the preparation of19-methoxy-1β-methyl-4-androstene-3β,17β-diol diacetate and19-methoxy-6α-methyl-4-androstene-3β,17β-diol diacetate.

EXAMPLE 13 3β,17β-Di-(1'-cyclopentyloxy)-19-methoxyandrost-4-ene

To a solution of 19-methoxyandrost-4-ene-3β,17β-diol in anhydrousbenzene containing p-toluenesulfonic acid is added cyclopentanonediethylketal. The mixture is heated for a period of one hour permittingdistillation of the alcohol which forms. After the addition of pyridine,the benzene is removed under vacuum and the residue which remains isrecrystallized from methanol to yield the desired3β,17β-di-(1'-cyclopentenyloxy)-19-methoxyandrost-4-ene.

Using the same procedure and substituting19-methoxy-1β-methyl-4-androstene-3β,17β-diol and19-methoxy-6α-methyl-4-androstene-3β,17β-diol for the19-methoxyandrost-4-ene-3β,17βdiol above results in the preparation of3β,17β-di-(1'-cyclopentenyloxy)-19-methoxy-1β-methyl-4-androstene and3β,17β-di-(1'-cyclopentenyloxy)-19-methoxy-6α-methyl-4-androstene.

EXAMPLE 14 Androst-4-ene-3β,17β,19-triol 17,19-diacetate

To a solution of lithium tri-t-butoxy-aluminum hydride intetrahydrofuran is added a tetrahydrofuran solution of17β,19-dihydroxyandrost-4-en-3-one diacetate. The resulting mixture isstirred at 20° C. for a period of 18 hours after which is added anaqueous solution of sodium potassium tartrate. The mixture is filteredand concentrated to a small volume under reduced pressure. Theconcentrate is taken up in ether and washed well with water. Thecombined ether extracts are dried over magnesium sulfate, filtered andthe ether removed under vacuum to yield a residue which whencrystallized from a mixture of acetone-hexane results in the preparationof the desired androst-4-ene-3β,17β,19-triol 17,19-diacetate.

Substituting 17β,19-hydroxy-1α-methyl-4-androsten-3-one dipropionate forthe 17β,19-dihydroxyandrost-4-en-3-one diacetate above, results in theformation of 1α-methyl-4-androstene-3β,17β,19-triol 17,19-dipropionate.

EXAMPLE 15 3β-(2'-Tetrahydropyranyloxy)androst-4-ene-17β,19-dioldiacetate

A solution of androst-4-ene-3β,17β,19-triol 17,19-diacetate,p-toluenesulfonic acid and 2,3-dihydropyran are stirred for a period ofthree hours at room temperature. The solution is diluted with ether,washed with an aqueous sodium carbonate solution, washed well withwater, dried over sodium sulfate and evaporated to dryness under reducedpressure. Crystallization of the residue from a mixture ofacetone-hexane results in the preparation of the desired3β-(2'-tetrahydropyranyloxy)androst-4-ene-17β,19-diol acetate.

Substituting 1α-methyl-4-androstene-3β,17β,19-triol 17,19-dipropionatefor the androst-4-ene-3β,17β,19-triol 17,19-diacetate above results inthe preparation of1α-methyl-3β-(2'-tetrahydropyranyloxy)-4-androstene-17β,19-dioldipropionate.

EXAMPLE 16 3β-(2'-Tetrahydropyranyloxy)androst-4-ene-17β,19-diol

A solution of 3β-(2'-tetrahydropyranyloxy)androst-4-ene-17β,19-dioldiacetate in methanol, is refluxed for a period of two hours with anaqueous solution of sodium carbonate. The solvent is removed and theresidue so obtained is purified by crystallization from methanol to formthe desired 3β-tetrahydropyranyloxy-androst-4-ene-17β,19-diol.

Substituting1α-methyl-3β-(2'-tetrahydropyranyloxy)-4-androstene-17β,19-dioldipropionate in the above procedure for3β-(2'-tetrahydropyranyloxy)androst-4-ene-17β,19-diol diacetate resultsin the preparation of1α-methyl-3β-(2'-tetrahydropyranyloxy)-4-androstene-17β,19-diol.

EXAMPLE 17 Androst-4-ene-3β,17β,19-triol 19-acetate

A tetrahydrofuran solution of 19-hydroxyandrost-4-ene-3,17-dione acetateis added to lithium tri-t-butoxyaluminum hydride in tetrahydrofuran andthe resultant solution stirred overnight at room temperature. An aqueoussolution of sodium potassium tartrate is added with stirring until areadily filterable precipitate forms. The filtrate is concentrated underreduced pressure and diluted with ether. The resulting solution iswashed with water, dried over magnesium sulfate, and the ether removedunder vacuum. The residual androst-4-ene-3β,17β,19-triol 19-acetate soobtained is recrystallized from acetone.

Substituting 19-hydroxy-1β-methyl-4-androstene-3,17-dione acetate and19-hydroxy-6α-methyl-4-androstene-3,17-dione acetate for19-hydroxyandrost-4-ene-3,17-dione acetate in the above procedureresults in the formation of 1β-methyl-4-androstene-3β,17β,19-triol19-acetate and 6α-methyl-4-androstene-3β,17β,19-triol 19-acetate.

EXAMPLE 18 3β,17β-Di-(triphenylsiloxy)androst-4-en-19-ol acetate

A solution of androst-4-ene-3β,17β,19-triol 19-acetate,triphenylchlorosilane, pyridine and toluene are refluxed for a period of24 hours. The resulting solid is filtered and the volatile materials areremoved under vacuum. The resultant oil is purified from methanol toyield the desired 3β,17β-di-(triphenylsiloxy)androst-4-en-19-ol acetate.

Substituting 1β-methyl-4-androstene-3β,17β,19-triol 19-acetate and6α-methyl-4-androstene-3β, 17β,19-triol 19-acetate for theandrost-4-ene-3β,17β,19-triol 19-acetate above, results in thepreparation of 1β-methyl-3β,17β-di-(triphenylsiloxy)-4-androsten-19-olacetate and 6α-methyl-3β,17β-di-(triphenylsiloxy)-4-androsten-19-olacetate.

EXAMPLE 19 3β,17β-Di-(triphenylsiloxy)androst-4-en-19-ol

To an ether solution of 3β,17β-di-(triphenylsiloxy)androst-4-en-19-olacetate is added a suspension of lithium aluminum hydride in ether.After refluxing for a period of one hour, water is cautiously added, theether solution is separated, dried over sodium sulfate and evaporatedunder reduced pressure. The residue when purified from an acetone-hexanemixture results in the preparation of the desired3β,17β-di-(triphenylsiloxy)androst-4-en-19-ol.

Following the same procedure and substituting1β-methyl-3β,17β-di-(triphenylsiloxy)-4-androsten-19-ol acetate and6α-methyl-3β,17β-di-(triphenylsiloxy)-4-androsten-19-ol acetate for the3β,17β-di-(triphenylsiloxy)androst-4-en-19-ol acetate above results inthe preparation of1β-methyl-3β,17β-di-(triphenylsiloxy)-4-androsten-19-ol and6α-methyl-3β,17β-di-(triphenylsiloxy)-4-androsten-19-ol, respectively.

EXAMPLE 20 17β-Hydroxy-19-(1'-methoxycyclopentyloxy)androst-4-en-3-oneacetate

To a suspension of 17β,19-dihydroxyandrost-4-en-3-one 17-acetate indioxane is added with stirring a mixture of cyclopentanone methylenolether and pyridine p-toluenesulfonate. The steroid quickly dissolves anda new precipitate forms which, after standing overnight, is collectedand recrystallized from a methanol-methylene chloride mixture to yieldthe desired 17β-hydroxy-19-(1'-methoxycyclopentyloxy)androst-4-en-3-oneacetate.

Following essentially the same procedures but substituting17β,19-dihydroxy-7α-methyl-4-androsten-3-one 17-acetate,17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one 17-acetate and17β,19-dihydroxy-1α-methyl-4-androsten-3-one 17-acetate for the17β,19-dihydroxyandrost-4-en-3-one 17-acetate above results in theformation of17β-hydroxy-19-(1'-methoxycyclopentyloxy)-7α-methyl-4-androsten-3-oneacetate,17β-hydroxy-19-(1'-methoxycyclopentyloxy)-1α,7α-dimethyl-4-androsten-3-oneacetate and17β-hydroxy-19-(1'-methoxycyclopentyloxy)1α-methyl-4-androsten-3-oneacetate.

EXAMPLE 21 19-(1'-Cyclopentenyloxy)-17β-hydroxyandrost-4-en-3-oneacetate

17β-Hydroxy-19-(1'-methoxycyclopentyloxy)androst-4-en-3-one acetate isdissolved in a dimethylformamide solution containing a drop of pyridine.The solution is refluxed permitting the alcohol which forms to distill.After one hour, the remaining solvent is removed under reduced pressureand the remaining residue is recrystallized from methanol to yield thedesired 19-(1'-cyclopentenyloxy)-17β-hydroxyandrost-4-en-3-one acetate.

Substituting17β-hydroxy-19-(1'-methoxycyclopentyl-oxy)-7α-methyl-4-androsten-3-oneacetate,17β-hydroxy-19-(1'-methoxycyclopentyloxy)-1α,7α-dimethyl-4-androsten-3-oneacetate and17β-hydroxy-19-(1'-methoxycyclopentyloxy)-1α-methyl-4-androsten-3-oneacetate for the17β-hydroxy-19-(1'-methoxycyclopentyloxy)androst-4-en-3-one acetateabove results in the formation of19-(1'-cyclopentenyloxy)-17β-hydroxy-7α-methyl-4-androsten-3-oneacetate,19-(1'-cyclopentenyloxy)-17β-hydroxy-1α,7α-dimethyl-4-androstene-3-oneacetate and19-(1'-cyclopentenyloxy)-17β-hydroxy-1α-methyl-4-androsten-3-oneacetate, respectively.

EXAMPLE 22 19-(1'-Cyclopentenyloxy)androst-4-en-3β,17β-diol

19-(1'-Cyclopentenyloxy)-17β-hydroxyandrost-4-en-3-one acetate isdissolved in anhydrous ether and added to a suspension of lithiumaluminum hydride in anhydrous ether. After refluxing for a period of onehour, water is cautiously added and the mixture filtered. The organiclayer is separated and dried over sodium sulfate. The dried solution isfiltered, concentrated in vacuo and the residue recrystallized frommethanol to yield the desired19-(1'-cyclopentenyloxy)androst-4-ene-3β,17β-diol.

Substituting19-(1'-cyclopentenyloxy)-17β-hydroxy-7α-methyl-4-androsten-3-oneacetate,19-(1'-cyclopentenyloxy)-17β-hydroxy-1α,7α-dimethyl-4-androsten-3-oneacetate and19-(1'-cyclopentenyloxy)-17β-hydroxy-1α-methyl-4-androsten-3-one acetatefor the 19-(1'-cyclopentenyloxy)-17β-hydroxyandrost-4-en-3-one acetateabove results in the formation of19-(1'-cyclopentenyloxy)-7α-methyl-4-androsten-3β,17β-diol,19-(1'-cyclopentenyloxy)-1α,7α-dimethyl-4-androsten-3β,17β-diol and19-(1'-cyclopentenyloxy)-1α-methyl-4-androsten-3β,17β-diol.

EXAMPLE 23 17β,19-dihydroxyandrost-4-en-3-one 19-acetate

A tetrahydrofuran solution of 19-hydroxyandrost-4-ene-3,17-dione acetateis added to a mixture of lithium tri-t-butoxyaluminum hydride containedin tetrahydrofuran. After stirring at room temperature overnight, anaqueous solution of potassium sodium tartrate is added with stirring toform a readily filterable white solid. The reaction mixture is filteredand the filtrate dried over magnesium sulfate. The dried solution isfiltered and the volatile materials removed in vacuo. The remainingresidue is dissolved in chloroform and stirred overnight with activatedmagnesium dioxide. The mixture is filtered and the filtrate concentratedunder reduced pressure. The residue so obtained is crystallized from anacetone-hexane mixture to yield the desired17β,19-dihydroxyandrost-4-en-3-one 19-acetate.

Substituting 19-hydroxy-1β-methyl-androst-4-ene-3,17-dione acetate and19-hydroxy-6α-methyl-androst-4-ene-3,17-dione acetate for the19-hydroxyandrost-4-ene-3,17-dione acetate above results in theformation of 17β,19-dihydroxy-1β-methylandrost-4-ene-3-one 19-acetateand 17β,19-dihydroxy-6α-methylandrost-4-en-3-one 19-acetate.

EXAMPLE 24 19-Hydroxy-17β-(1'-methoxycyclohexyloxy)androst-4-en-3-oneacetate

To a suspension of 17β,19-dihydroxyandrost-4-en-3-one 19-acetate inanhydrous dioxane is added cyclohexanone methyl enolether and pyridinep-toluenesulfonate. After standing overnight, the precipitate whichforms is collected and crystallized from methanol to give the desired19-hydroxy-17β-(1'-methoxycyclohexyloxy)androst-4-en-3-one acetate.

Substituting 17β,19-dihydroxy-1β-methylandrost-4-en-3-one 19-acetate and17β,19-dihydroxy-6α-methylandrost-4-en-3-one 19-acetate for the17β,19-dihydroxyandrost-4-en-3-one 19-acetate above results in theformation of19-hydroxy-17β-(1'-methoxycyclohexyloxy)-1β-methylandrost-4-en-3-oneacetate and19-hydroxy-17β-(1'-methoxycyclohexyloxy)-6α-methylandrost-4-en-3-oneacetate.

EXAMPLE 25 19-Hydroxy-17β-(1'-methoxycyclohexyloxy)androst-4-en-3-one

A solution of 19-hydroxy-17β-(1'-methoxycyclohexyloxy)androst-4-en-3-oneacetate in aqueous methanol containing sodium carbonate is refluxed fora period of two hours. The solution is poured into water, extracted withmethylene chloride, the organic layers separated, combined and driedover magnesium sulfate. The filtrate is evaporated in vacuo and theresidue recrystallized from methanol resulting in the formation of thedesired 19-hydroxy-17β-(1'-methoxycyclohexyloxy)androst-4-en-3-one.

Following essentially the same procedure and substituting19-hydroxy-17β-(1'-methoxycyclohexyloxy)-β-methylandrost-4-en-3-oneacetate and19-hydroxy-17β-(1'-methoxycyclohexyloxy)-6α-methylandrost-4-en-3-oneacetate for the19-hydroxy-17β-(1'-methoxycyclohexyloxy)androst-4-en-3-one acetateabove, results in the preparation of19-hydroxy-17β-(1'-methoxycyclohexyloxy)-1β-methylandrost-4-en-3-one and19-hydroxy-17β-(1'-methoxycyclohexyloxy)-6α-methylandrost-4-en-3-one,respectively.

EXAMPLE 26 19-t-Butyldimethylsiloxy-4-androstene-3,17-dione

19-Hydroxy-4-androstene-3,17-dione, t-butyldimethylsilylchloride andpyridine are mixed in dry dimethylformamide and heated on a steam bathovernight. The reaction mixture is poured onto water and stirred wellfor 15 minutes. The resulting solid is filtered and dissolved inmethylenechloride, dried over magnesium sulfate and the solvent removed.The residue is crystallized from an acetone-hexane solution to yield19-t-butyldimethylsiloxy-4-androstene-3,17-dione.

Following essentially the same procedure and substituting19-hydroxy-6α-methyl-4-androstene-3,17-dione for the19-hydroxy-4-androstene-3,17-dione above results in the preparation of19-t-butyldimethylsiloxy-6α-methyl-4-androstene-3,17-dione.

EXAMPLE 27 19-(4'-Tetrahydropyranyloxy)androst-4-ene-3,17-dione

19-Hydroxy-4-androstene-3,17-dione is dissolved in dimethylformamide andheated to 50° C. 4-Bromotetrahydropyran is added to this solutionfollowed by the addition of sodium hydride. Heating and stirring iscontinued for a period of four hours, the reaction mixture cooled andpoured onto ice water. The resulting oil which forms is extracted withether and the combined ether extracts are washed with water, dried overmagnesium sulfate and concentrated to leave a cream-colored solid.Crystallization of this residue from hexane gives pure19-(4'-tetrahydropyranyloxy)-androst-4-ene-3,17-dione.

Following essentially the same procedure but substituting19-hydroxy-1β-methylandrost-4-ene-3,17-dione and19-hydroxy-6α-methyl-4-androstene-3,17-dione for the19-hydroxy-4-androstene-3,17-dione above, accordingly results in thepreparation of1β-methyl-19-(4'-tetrahydropyranyloxy)androst-4-ene-3,17-dione and6α-methyl-19-(4'-tetrahydropyranyloxy)androst-4-ene-3,17-dione.

EXAMPLE 284-Methyl-17β,19-di-(4'-tetrahydropyranyloxy)-4-androsten-3-one

17β,19-Dihydroxy-4-methyl-4-androsten-3-one and 4-bromotetrahydropyranare heated to 50° in dimethylformamide. Sodium hydride is added slowlyand stirring at 50° C. is continued for a period of 18 hours. Thereaction mixture is poured onto ice water and the water extracted withether. The combined ether extracts are washed with water, dried overmagnesium sulfate and concentrated to dryness. The residue remaining iscrystallized from hexane to yield4-methyl-17β,19-di-(4'-tetrahydropyranyloxy)-4-androsten-3-one.

Following the same procedure and substituting17β,19-dihydroxy-4-androsten-3-one,17β,19-dihydroxy-1α-methyl-4-androsten-3-one and 17β,19-dihydroxy-7 60-methyl-4-androsten-3-one for the17β,19-dihydroxy-4-methyl-4-androsten-3-one above, results in theformation of 17β,19-di-(4'-tetrahydropyranyloxy)-4-androsten-3-one,1α-methyl-17β,19-di-(4'-tetrahydropyranyloxy)-4-androsten-3-one and7α-methyl-17β,19-di-(4'-tetrahydropyranyloxy)-4-androsten-3-one,respectively.

EXAMPLE 29 1α-Methyl-4-androstene-17β,19-diol

17β,19-Dihydroxy-1α-methyl-4-androsten-3-one in acetic acid is treatedwith ethanedithiol and p-toluenesulfonic acid. After 4 hours at roomtemperature, the solution is poured onto water and the mixture extractedwith methylenechloride. The methylenechloride extracts are washed wellwith water, sodium hydroxide solution, water, dried over sodium sulfateand evaporated under reduced pressure to leave17β,19-dihydroxy-1α-methyl-4-androsten-3-one 3-ethylenethioketal whichis recrystallized once from a solution of acetone-hexane.

Raney nickel is added to a solution of17β,19-dihydroxy-1α-methyl-4-androsten-3-one 3-ethylenethioketal inmethanol and the resulting suspension is refluxed for four hours withrapid stirring. The suspension is cooled, filtered and the solventevaporated. The remaining residue is chromatographed on silica gel andeluted with methylenechloride. Recrystallization from acetone-hexaneyields the compound 1α-methyl-4-androstene-17β,19-diol.

Substituting 17β,19-dihydroxy-1α,17α-dimethyl-4-androsten-3-one and17β,19-dihydroxy-4-methyl-4-androsten-3-one in lieu of the17β,19-dihydroxy-1α-methyl-4-androsten-3-one above, results in thepreparation of 1α,17α-dimethyl-4-androstene-17β,19-diol and4-methyl-4-androsten-17β,19-diol, respectively.

EXAMPLE 30 1α-Methyl-4-androstene-17β,19-diol dipropionate

1α-Methyl-4-androstene-17β,19-diol is dissolved in pyridine andpropionic anhydride and stirred under nitrogen at room temperatureovernight. Ethanol is added and stirring continued for an additional 2hours. The solvents are removed under vacuum and the residue iscrystallized from hexane to yield 1α-methyl-4-androstene-17β,19-dioldipropionate.

Substituting 1α,17α-dimethyl-4-androstene-17β,19-diol and4-methyl-4-androstene-17β,19-diol for the1α-methyl-4-androstene-17β,19-diol above results in the preparation of1α,17α-dimethyl-4-androstene-17β,19-diol dipropionate and4-methyl-4-androstene-17β,19-diol dipropionate.

EXAMPLE 31 1α-Methyl-4-androstene-17β,19-diol 17-propionate

To a solution of 1α-methyl-4-androstene-17β,19-diol dipropionate in 10%aqueous methanol is added 1 equivalent sodium bicarbonate and thesolution is heated under reflux for one hour. Methanol is removed undervacuum to half volume and the concentrate is poured onto water. Thesolid is filtered, air dried and crystallized from hexane to give1α-methyl-4-androstene-17β,19-diol 17-propionate.

Substituting 1α,17α-dimethyl-4-androsten-17β,19-diol dipropionate and4-methyl-4-androstene-17β,19-diol dipropionate in the above procedurefor the 1α-methyl-4-androstene-17β,19-diol dipropionate results in theformation of 1α,17α-dimethyl-4-androsten-17β,19-diol 17-propionate and4-methyl-4-androstene-17β,19-diol 17-propionate, respectively.

EXAMPLE 32 4-Androstene-3α,17β,19-triol

A 1 M solution of lithium tri-sec-butylborohydride in tetrahydrofuranunder nitrogen is cooled in a dry ice-acetone bath to about -78° C. and17β,19-dihydroxy-4-androsten-3-one in tetrahydrofuran is slowly added.The reaction mixture is stirred for a period of two hours at thistemperature, warmed to 0° C. and stirring continued for an additionaltwo hours. The reaction mixture is decomposed by the addition of 3 Nsodium hydroxide followed by the addition of a 30% hydrogen peroxidesolution. Solid potassium carbonate is added and the tetrahydrofuransolution decanted. The solid residue is washed with freshtetrahydrofuran and the combined tetrahydrofuran solutions are driedover anhydrous sodium sulfate, filtered, and evaporated. The residue iscrystallized from acetone to yield 4-androstene-3α,17β-19-triol.

Following essentially the same procedure and substituting17β,19-dihydroxy-7α-methyl-4-androsten-3-one diacetate,7α-methyl-17β,19-di-(2'-tetrahydropyranyloxy)-4-androsten-3-one and19-hydroxy-1β-methyl-4-androsten-3,17-dione for the17β,19-dihydroxy-4-androsten-3-one above results in the preparation of7α-methyl-4-androstene-3α,17β,19-triol 17β,19-diacetate,7α-methyl-17β,19-di-(2'-tetrahydropyranyloxy)-4-androsten-3.alpha.-oland 1β-methyl-4-androstene-3α,17β,19-triol, respectively.

EXAMPLE 33 7α-Methyl-4-androstene-3α,17β,19-triol

A 0.5 M solution of potassium tri-sec-butylborohydride intetrahydrofuran under nitrogen is cooled to -78° C. in a dry ice-acetonebath. 17β,19-Dihydroxy-7α-methyl-4-androsten-3-one in tetrahydrofuran isadded slowly and the reaction mixture is stirred for a period of twohours at this temperature, warmed to 0° C., and stirred for anadditional two hours. The reaction mixture is decomposed by the additionof 3 N sodium hydroxide followed by a 30% hydrogen peroxide solution.Solid potassium carbonate is added and the tetrahydrofuran solutiondecanted. The solid residue is washed with fresh tetrahydrofuran and thecombined tetrahydrofuran solutions are dried over anhydrous sodiumsulfate, filtered and the filtrate removed by evaporation. The residueis crystallized from acetone to yield7α-methyl-4-androstene-3α,17β,19-triol.

Substituting 17β,19-dihydroxy-4,17α-dimethyl-4-androsten-3-one and19-hydroxy-6α-methyl-4-androstene-3,17-dione for17α,19-dihydroxy-7α-methyl-4-androsten-3-one above results in thepreparation of 4,17α-dimethyl-4-androstene-3α,17β,19-triol and6α-methyl-4-androstene-3α,17β,19-triol, respectively.

EXAMPLE 34 17β,19-Dihydroxy-1,4-androstadien-3-one dipropionate

17β,19-Dihydroxy-4-androsten-3-one dipropionate anddichlorodicyanobenzoquinone are refluxed in anhydrous dioxane for aperiod of 48 hours. The mixture is cooled and filtered and the filtrateconcentrated under vacuum. Methylenechloride is added and the resultingmixture filtered. The filtrate is washed well with water, dried oversodium sulfate and the solvent removed. Chromatography of the residue onsilica gel and elution with methylenechloride provides a solid which iscrystallized from acetone-hexane to yield the desired17β,19-dihydroxy-1,4-androstadien-3-one dipropionate.

Substituting 17β,19-dihydroxy-17α-methyl-4-androsten-3-one dipropionateand 17β,19-dihydroxy-6α-methyl-4-androsten-3-one dipropionate for17β,19-dihydroxy-4-androsten-3-one dipropionate above results in theformation of 17β,19-dihydroxy-17α-methyl-1,4-androstadien-3-onedipropionate and 17β,19-dihydroxy-6α-methyl-1,4-androstadien-3-onedipropionate, respectively.

EXAMPLE 35 17β,19-Dihydroxy-1α-methyl-4-androst-en-3-one dipropionate

A solution of lithium dimethylcopper is prepared under nitrogen by theaddition of 1.6 M ethereal methyllithium to an ether slurry of cuprousiodide at 0° C. The solution is stirred at 0° C. for 20 minutes and thena solution of 17β,19-dihydroxy-1,4-androstadien-3-one dipropionate inanhydrous tetrahydrofuran is added slowly and stirred for one half hour.The mixture is poured onto a saturated aqueous ammonium chloridesolution, benzene is added and the resulting mixture filtered throughdiatomaceous earth. The organic layer is washed with aqueous ammoniumchloride, water, dried over magnesium sulfate and evaporated to dryness.The residue is passed through a silica gel column and eluted withbenzene. Recrystallization from hexane yields17β,19-dihydroxy-1α-methyl-4-androsten-3-one dipropionate.

Substituting 17β,19-dihydroxy-17α-methyl-1,4-androstadien-3-onedipropionate and 17β,19-dihydroxy-6α-methyl-1,4-androstadien-3-onedipropionate for 17β,19-dihydroxy-1,4-androstadien-3-one in the aboveprocedure results in the formation of17β,19-dihydroxy-1α,17α-dimethyl-4-androsten-3-one dipropionate and17β,19-dihydroxy-1α,6α-dimethyl-4-androsten-3-one dipropionate.

EXAMPLE 36 17β,19-Dihydroxy-1α-methyl-4-androsten-3-one

A solution of 17β,19-dihydroxy-1α-methyl-4-androsten-3-one dipropionatein methanol is refluxed for two hours with aqueous sodium carbonate. Thesolvent is removed and the residue dissolved in chloroform. Thechloroform solution is washed well with water, dried over magnesiumsulfate and evaporated under vacuum. The residue which remains iscrystallized from acetonitrile to yield17β,19-dihydroxy-1α-methyl-4-androsten-3-one.

Substituting 17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-onedipropionate and 17β,19-dihydroxy-1α,6α-dimethyl-4-androsten-3-onedipropionate in the above procedure results in the preparation of17β,19-dihydroxy-1α,17α-dimethyl-4-androsten-3-one and17β,19-dihydroxy-1α,6α-dimethyl-4-androsten-3-one, respectively.

EXAMPLE 37 1α-Methyl-4-androstene-3β,17β,19-triol

17β,19-Dihydroxy-1α-methyl-4-androsten-3-one is dissolved in ethanol andsodium borohydride is added slowly under nitrogen. After stirring atroom temperature for 4 hours, the solution is poured onto ice watercontaining a few drops of acetic acid. The solid which forms is filteredand recrystallized from ethanol to yield1α-methyl-4-androstene-3β,17β,19-triol.

Substituting 17β,19-dihydroxy-1α,17α-dimethyl-4-androsten-3-one and17β,19-dihydroxy-1α,6α-dimethyl-4-androsten-3-one for17β,19-dihydroxy-1α-methyl-4-androsten-3-one above results in theformation of 1α,17α-dimethyl-4-androstene-3β,17β,19-triol and1α,6α-dimethyl-4-androstene-3β,17β,19-triol, respectively.

EXAMPLE 38 1β,2β-Methylene-4-androstene-3,17-dione

To a solution of potassium t-butoxide in dimethylsulfoxide at 25° C.under nitrogen is added 1,4-androstadiene-3,17-dione indimethylsulfoxide with stirring. After fifteen minutes the mixture ispoured onto cold aqueous ammonium chloride. The solid is rapidlyfiltered, washed well with water and dissolved in ether. The ethersolution is washed again with water, dried over sodium sulfate andevaporated at room temperature to yield 1,5-androstadiene-3,17-dione.

A tetrahydrofuran solution of 1,5-androstadiene-3,17-dione is addedunder nitrogen to a solution of lithium tri-t-butoxyaluminum hydride intetrahydrofuran. After stirring at room temperature overnight, anaqueous solution of potassium sodium tartrate is added with stirring toform a readily filterable white solid. The reaction mixture is filteredand the filtrate dried over magnesium sulfate and the solvent removed.The residue which remains is recrystallized from acetone to yield1,5-androstadiene-3β,17β-diol.

To a stirred solution of 1,5-androstadiene-3β,17β-diol in a mixture ofdry ether and glyme is added zinc-copper couple and methylene iodide.This reaction mixture is refluxed for 4 hours, cooled to roomtemperature, diluted with ether and filtered. The filtrate is washedwith aqueous sodium chloride, water and dried over anhydrous magnesiumsulfate. The ether is removed under reduced pressure and the residuecrystallized from acetone-hexane to yield1β,2β-methylene-5-androstene-3β,17β-diol.

The 1β,2β-methylene-5-androstene-3β,17β-diol is dissolved in acetone andJones reagent added until a persistent yellow-orange color appears.After stirring at room temperature for ten minutes the mixture is pouredonto ice-water and the precipitate is collected by filtration. Theprecipitate is dissolved in a solution of sodium methoxide in methanoland stirred for a period of 30 minutes at room temperature. The methanolis removed and the residue triturated with water. The solid whichresults is filtered and crystallized from acetone to yield1β,2β-methylene-4-androstene-3,17-dione.

EXAMPLE 39 1β-Methyl-4-androstene-3,17-dione

1β,2β-Methylene-4-androstene-3,17-dione, zinc powder, and acetic acidare refluxed together for a period of 1 hour. On cooling benzene isadded, the suspension filtered and the filtrate taken to dryness undervacuum. The residue is chromatographed on silica gel and eluted withmethylenechloride. Recrystallization from acetone-hexane yields1β-methyl-4-androstene-3,17-dione.

EXAMPLE 40 1β-Methyl-5-androstene-3β,17β-diol, diacetate

To a solution of potassium t-butoxide in dimethylsulfoxide at 25° C.under nitrogen is added 1β-methyl-4-androstene-3,17-dione indimethylsulfoxide with stirring. After 15 minutes the mixture is pouredonto cold aqueous ammonium chloride. The solid is rapidly filtered,washed well with water and dissolved in ether. The ether is washed withwater, dried over sodium sulfate and removed at room temperature toyield 1β-methyl-5-androstene-3,17-dione.

A tetrahydrofuran solution of 1β-methyl-5-androstene-3,17-dione is addedunder nitrogen to a solution of lithium tri-t-butoxyaluminum hydride intetrahydrofuran. After stirring at room temperature for a period of 18hours, an aqueous solution of potassium sodium tartrate is added withstirring to form a readily filterable white solid. The reaction mixtureis filtered, the filtrate dried over magnesium sulfate, and the solventremoved. The residue is crystallized from an acetone-hexane solution toyield 1β-methyl-5-androstene-3β,17β-diol.

The 1β-methyl-5-androstene-3β,17β-diol is dissolved in acetic anhydrideand pyridine and kept at room temperature for a period of 20 hours. Thesolvent is removed under vacuum and the residue recrystallized fromhexane to yield 1β-methyl-5-androstene-3β,17β-diol diacetate.

EXAMPLE 41 5α-Bromo-1β-methylandrostane-3β,6β,17β-triol 3,17-diacetate

A solution of 1β-methyl-5-androstene-3β,17β-diol, diacetate in ether iscooled to -5° C. in an ice-methanol bath and a solution of aqueousperchloric acid added followed by the addition of N-bromoacetamide.Stirring at -5° C. is continued for a period of two hours followed bythe addition of water. The ether layer is washed with water untilneutral and concentrated to a small volume at room temperature. Theproduct is filtered and crystallized from a solution of acetone-hexaneto yield 5α-bromo-1β-methylandrostane-3β,6β,17β-triol 3,17-diacetate.

Following essentially the same procedure and substituting4α-methyl-5-androstene-3β,17β-diol, diacetate,6-methyl-5-androstene-3β,17β-diol, diacetate,7α-methyl-5-androstene-3β,17β-diol, diacetate and1β,17α-dimethyl-5-androstene-3β,17β-diol diacetate for the1β-methyl-5-androstene-3β,17β-diol, diacetate above, results in theformation of 5α-bromo-4α-methylandrostane-3β,6β,17β-triol3,17-diacetate, 5α-bromo-6-methylandrostane-3β,6β,17β-triol3,17-diacetate, 5α-bromo-7α-methylandrostane-3β,6β,17β-triol3,17-diacetate and5α-bromo-1β,17α-dimethylandrostane-3β,6β,17.beta.-triol 3,17-diacetate.respectively.

EXAMPLE 42 5α-Bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-dioldiacetate

A stirred suspension of lead tetraacetate and calcium carbonate incyclohexane is refluxed for 30 minutes to which is added iodine and5α-bromo-1β-methyl-androstane-3β,6β,17β-triol 3,17-diacetate. Thestirred mixture is irradiated with a 600 Watt lamp which maintains themixture at reflux. After the iodine color has disappeared the mixture iscooled, filtered and the residue washed with ether. The filtrates arecombined, concentrated to 1/5 volume, washed with a 10% sodiumthiosulfate solution, followed by a water wash, dried over magnesiumsulfate and evaporated under reduced pressure to a semi-solid residuewhich is crystallized from acetone-hexane to yield5α-bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-diol diacetate.

Following essentially the same procedure and substituting5α-bromo-4α-methylandrostane-3β,6β,17β-triol 3,17-diacetate,5α-bromo-6-methylandrostane-3β,6β,17β-triol 3,17-diacetate,5α-bromo-7α-methylandrostane-3β,6β,17β-triol 3,17-diacetate and5α-bromo-1β,17α-dimethylandrostane-3β,6β,17.beta.-triol 3,17-diacetatefor the 5α-bromo-1β-methyl-androstane-3β,6β,17β-triol 3,17-diacetateabove results in the preparation of5α-bromo-4α-methyl-6β,19-oxidoandrostane-3β,17β-diol diacetate,5α-bromo-6-methyl-6β,19-oxidoandrostane-3β,17β-diol diacetate,5α-bromo-7α-methyl-6β,19-oxidoandrostane-3β,17β-diol diacetate and5α-bromo-1β,17α-dimethyl-6β,19-oxidoandrostane-3.beta.,17β-dioldiacetate, respectively.

EXAMPLE 43 5α-Bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-diol

To a solution of 5α-bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-dioldiacetate in methanol is added a 5% aqueous potassium carbonate solutionand the mixture refluxed for a period of about three hours. The methanolis removed and water added. The solid which forms is filtered andcrystallized from aqueous methanol to yield5α-bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-diol.

Substituting 5α-bromo-4α-methyl-6β,19-oxidoandrostane-3β,17β-dioldiacetate, 5α-bromo-6-methyl-6β,19-oxidoandrostane-3β,17β-dioldiacetate, 5α-bromo-7α-methyl-6β,19-oxidoandrostane-3β,17β-dioldiacetate and5α-bromo-1β,17α-dimethyl-6β,19-oxidoandrostane-3.beta.,17β-dioldiacetate for the 5α-bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-dioldiacetate results in the preparation of5α-bromo-4α-methyl-6β,19-oxidoandrostane-3β,17β-diol,5α-bromo-6-methyl-6β,19-oxidoandrostane-3β,17β-diol,5α-bromo-7α-methyl-6β,19-oxidoandrostane-3β,17β-diol and5α-bromo-1β,17α-dimethyl-6β,19-oxidoandrostane-3.beta.,17β-diol,respectively.

EXAMPLE 44 5α-Bromo-1β-methyl-6β,19-oxidoandrostane-3,17-dione

5α-Bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-diol is dissolved inacetone and Jones reagent added until a persistent yellow-orange colorappears. Stirring is continued for about 30 minutes whereupon thesolution is poured onto water. The solid is filtered and recrystallizedfrom acetone-hexane to yield5α-bromo-1β-methyl-6β,19-oxidoandrostane-3,17-dione.

Substituting 5α-bromo-4α-methyl-6β,19-oxidoandrostane-3β,17β-diol,5α-bromo-6-methyl-6β,19-oxidoandrostane-3β,17β-diol,5α-bromo-7α-methyl-6β,19-oxidoandrostane-3β,17β-diol and5α-bromo-1β,17α-dimethyl-6β,19-oxidoandrostane-3.beta.,17β-diol for the5α-bromo-1β-methyl-6β,19-oxidoandrostane-3β,17β-diol above results inthe preparation of 5α-bromo-4α-methyl-6β,19-oxidoandrostane-3,17-dione,5α-bromo-6-methyl-6α,19-oxidoandrostane-3,17-dione,5α-bromo-7α-methyl-6β,19-oxidoandrostane-3,17-dione and5α-bromo-17β-hydroxy-1β,17α-dimethyl-6β,19-oxidoandrostane-3-one,respectively.

EXAMPLE 45 19-Hydroxy-1β-methyl-4-androstene-3,17-dione

Zinc powder is added to a solution of5α-bromo-1β-methyl-6β,19-oxidoandrostane-3,17-dione in ethanol and themixture heated under reflux with stirring for a period of about 3 hours.The suspension is filtered and the zinc cake washed with hot ethanol.Removal of the solvent from the combined filtrates affords a residuewhich is recrystallized from an acetone-hexane solution to yield19-hydroxy-1β-methyl-4-androstene-3,17-dione.

Following essentially the same procedure but substituting5α-bromo-4α-methyl-6β,19-oxidoandrostane-3,17-dione,5α-bromo-6-methyl-6β,19-oxidoandrostane-3,17-dione,5α-bromo-7α-methyl-6β,19-oxidoandrostane-3,17-dione and5α-bromo-17β-hydroxy-1β,17α-dimethyl-6β,19-oxidoandrostan-3-one for the5α-bromo-1β-methyl-6β,19-oxidoandrostane-3,17-dione above results in thepreparation of 19-hydroxy-4-methyl-4-androstene-3,17-dione,19-hydroxy-6α-methyl-4-androstene-3,17-dione,19-hydroxy-7α-methyl-4-androstene-3,17-dione and17β,19-dihydroxy-1β,17α-dimethyl-4-androstene-3-one, respectively.

EXAMPLE 46 17β,19-Dihydroxy-4,6α,17α-trimethyl-4-androsten-3-one

A mixture of 17β,19-dihydroxy-6α,17α-dimethyl-4-androsten-3-one,thiophenol, 40% aqueous formaldehyde, triethylamine and ethanol isheated under reflux for a period of about 48 hours. The cooled solutionis poured into aqueous sodium hydroxide and the product isolated byether extraction. The ether extract is washed with water and dried overmagnesium sulfate. The residue left after evaporation of the ether istriturated with hexane to remove condensation products derived from thethiophenol and formaldehyde. The17β,19-dihydroxy-6α-methyl-4-phenylthiomethyl-4-androsten-3-one soobtained is desulfurized by dissolving in acetone and adding to asuspension of Raney Nickel in refluxing acetone. The resulting mixtureis heated under reflux while stirring for about 5 hours. The hotsolution is filtered and the nickel washed with boiling ethanol andwater. The combined filtrates are concentrated under vacuum whereuponthe product separates as a solid. Recrystallization from acetonehexaneyields 17β,19-dihydroxy-4,6α,17α-trimethyl-4-androsten-3-one.

Following essentially the same procedure and substituting17β,19-dihydroxy-4-androsten-3-one,19-hydroxy-1α-methyl-4-androstene-3,17-dione and17β,19-dihydroxy-7α-methyl-4-androstene-3-one for the17β,19-dihydroxy-6α,17α-dimethyl-4-androsten-3-one above results in thepreparation of 17β,19-dihydroxy-4-methyl-4-androsten-3-one,19-hydroxy-1α,4-dimethyl-4-androstene-3,17-dione, and17β,19-dihydroxy-4,7α-methyl-4-androsten-3-one, respectively.

EXAMPLE 47 17β,19-Dihydroxy-4,17α-dimethyl-4-androsten-3-one

A solution of 17β,19-dihydroxy-17α-methyl-4-androsten-3-one in t-butanolis heated to boiling and added to a boiling solution of potassiumt-butoxide in t-butanol. Methyl chloride in t-butanol is slowly added.The solution is cooled, acidified with concentrated hydrochloric acid,and diluted with water. The t-butanol is removed under vacuum and theaqueous layer extracted with ethylacetate. The extract is washed withwater, dried over magnesium sulfate and evaporated in vacuo. The residuewhich remains is chromatographed on silica gel and eluted withethylacetate. The eluant is crystallized from acetonitrile to yield17β,19-dihydroxy-4,17α-dimethyl-4-androstene-3-one.

EXAMPLE 48 5α,6α-Epoxy-17α-methyl-androstane-3β,17β,19-triol3,19-diacetate

A solution of 17α-methyl-5-androstene-3β,17β,19-triol 3,19-diacetate inchloroform is chilled to 0° C. and treated with m-chloroperbenzoic acidin chloroform which is precooled to 0° C. The mixture is stirred andallowed to warm to room temperature. After a period of about 48 hours,the solution is washed with a 10% sodium sulfite solution, a solution ofsodium thiosulfate, a sodium bicarbonate solution and water. Thechloroform extract is dried over magnesium sulfate and evaporated invacuo. The residue which remains is crystallized from methanol to give5α,6α-epoxy-17α-methylandrostane-3β,17β,19-triol 3,19-diacetate.

EXAMPLE 49 6β,17α-Dimethyl-androstane-3β,5α,17β,19-tetrol

Ethereal methylmagnesium bromide is added slowly to a stirred solutionof 5α,6α-epoxy-17α-methylandrostane-3β,17β,19-triol 3,19-diacetate intetrahydrofuran. The solution is heated under reflux for about 24 hours,cooled and poured onto a saturated aqueous ammonium chloride solution.The mixture is extracted with ethylacetate, washed with brine, driedover magnesium sulfate and the solvent removed under reduced pressure.The residue which remains is crystallized from ethyl acetate to yield6β,17α-dimethylandrostane-3β,5α,17β,19-tetrol.

EXAMPLE 50 17β-Hydroxy-6α,17α-dimethyl-4-androstene-3,19-dione

6β,17α-Dimethylandrostane-3β,5α,17β,19-tetrol is dissolved in acetoneand Jones reagent added with stirring. After about 15 minutes thereaction mixture is poured onto water. After stirring for about 30minutes the solid is filtered and dissolved in methanol containingsodium hydroxide. After about 2 hours the methanol is removed at roomtemperature and the residue triturated with water. Recrystallization ofthis residue from an acetone-water solution yields17β-hydroxy-6α,17α-dimethyl-4-androstene-3,19-dione.

EXAMPLE 51 6α,17α-Dimethyl-4-androstene-3β,17β,19-triol

Sodium borohydride is added under nitrogen with stirring to a solutionof 17β-hydroxy-6α,17α-dimethyl-4-androstene-3,19-dione in methanol.After about 5 hours at room temperature, the solution is poured ontowater containing a few drops of acetic acid. The solution which forms isfiltered and crystallized from methanol to yield6α,17α-dimethyl-4-androstene-3β,17β,19-triol.

EXAMPLE 52 17β,19-Dihydroxy-6α,17α-dimethyl-4-androsten-3one

6α,17α-Dimethyl-4-androstene-3β,17β,19-triol is dissolved in hotchloroform and cooled to 15° C. Activated manganese dioxide is added atsuch a rate that the temperature does not rise above 25° C. Stirring iscontinued at room temperature for about 1 hour. The manganese dioxide isremoved by filtration through diatomaceous earth and the chloroformdistilled under vacuum. The residue which remains is crystallized fromacetonitrile to yield17β,19-dihydroxy-6α,17α-dimethyl-4-androsten-3-one.

EXAMPLE 53 6α,17α-Dimethyl-4-androstene-17β,19-diol

17β,19-Dihydroxy-6α,17α-dimethyl-4-androstene-3-one is dissolved inethane dithiol. Boron trifluorideetherate is added and after about 30minutes the reaction mixture is diluted with ether, washed with a 1 Nsodium hydroxide solution until the odor is removed and the organiclayer dried over magnesium sulfate. Evaporation of the ether leaves asolid which is triturated with hexane. Filtration results in collectionof the thioketal which is dissolved in methanol. Raney Nickel is addedand the resulting suspension is heated under reflux for about 5 hourswhile being stirred. On cooling the nickel is removed by filtration andthe solvent evaporated. Chromatography of the residue on silica gel,elution with benzene-ethylacetate and crystallization from hexane yieldsthe desired 6α,17α-dimethyl-4-androstene-17β,19-diol.

EXAMPLE 54 19-Acetoxy-5α,6α-epoxy-androstane-3,17-dione bisethyleneketal

To a solution of 19-acetoxy-5-androstene-3,17-dione bis ethyleneketal inmethylenechloride which has been precooled to 0° C. is added amethylenechloride solution of m-chloroperbenzoic acid also precooled to0° C. The mixture is stirred at room temperature for about 24 hours andadditional methylenechloride is added. The methylenechloride solution iswashed sequentially with solutions of sodium sulfite, sodiumthiosulfate, sodium bicarbonate and finally with water. Themethylenechloride extract is dried over magnesium sulfate and taken todryness under reduced pressure. Recrystallization of the residue frommethanol yields 19-acetoxy-5α,6α-epoxy-androstane-3,17-dione bisethyleneketal.

EXAMPLE 55 5α,19-Dihydroxy-6β-methylandrostane-3,17-dione bisethyleneketal

A solution of 19-acetoxy-5α,6α-epoxyandrostane-3,17-dione bisethyleneketal in tetrahydrofuran is added to an ethereal solution ofmethylmagnesium bromide. The resultant mixture is refluxed forapproximately 4 hours, cooled and treated with a saturated aqueousammonium chloride solution. The organic layer obtained is evaporated,extracted with ethylacetate, washed with brine, dried over magnesiumsulfate and concentrated. Crystallization of the residue from a solutionof acetone-hexane yields 5α,19-dihydroxy-6β-methylandrostane-3,17-dionebis ethyleneketal.

EXAMPLE 56 19-Hydroxy-6α-methyl-4-androstene-3,17-dione

A solution of 5α,19-dihydroxy-6β-methylandrostane-3,17-dione bisethyleneketal in methanol containing aqueous sulfuric acid is heated toits reflux temperature and the solvent removed. Crystallization of theresidue from an acetone-hexane solution yields19-hydroxy-6α-methyl-4-androstene-3,17-dione.

EXAMPLE 57 4,6-Androstadiene-3,17,19-trione

19-Hydroxy-4-androstene-3,17-dione and chloranil are dissolved int-butanol and rapidly brought to reflux. The t-butanol is removed bydistillation at atmospheric pressure at such a rate so that the totalreflux and distillation time equals one hour. The dark pasty residue istriturated with hot chloroform and cooled. The solid which remains isremoved by filtration and the filtrate successively extracted withwater, a 2% sodium hydroxide solution and again with water. The organiclayer is dried over magnesium sulfate and the solvent removed undervacuum to yield 19-hydroxy-4,6-androstadiene-3,17-dione. The diene soprepared is dissolved in acetone and chilled in an ice bath. Jonesreagent is added over a period of about 10 minutes and stirringcontinued for an additional 45 minutes. The mixture is poured ontowater. The solid which forms is filtered and recrystallized from benzeneto yield 4,6-androstadiene-3,17,19-trione.

Following essentially the same procedure and substituting19-hydroxy-4-methyl-4-androstene-3,17-dione,17β,19-dihydroxy-17α-methyl-4-androsten-3-one and17β,19-dihydroxy-17α-propinyl-4-androsten-3-one for the19-hydroxy-4-androstene-3,17-dione above results in the preparation of4-methyl-4,6-androstadiene-3,17,19-trione,17β-hydroxy-17α-methyl-4,6-androstadiene-3,19-dione and17β-hydroxy-17α-propinyl-4,6-androstadiene-3,19-dione.

EXAMPLE 58 7α-Methyl-4-androstene-3β,17β,19-triol

A solution of lithium dimethylcopper is prepared under nitrogen by theaddition of 1.6 M ethereal methyllithium to a slurry of cuprous iodidein anhydrous ether at 0° C. The solution is stirred at 0° C. for 20minutes, a solution of 4,6-androstadiene-3,17,19-trione in anhydroustetrahydrofuran is added over a period of about 20 minutes and stirringcontinued for an additional 30 minutes. The mixture is poured onto asaturated aqueous ammonium chloride solution, benzene is added and theresulting mixture is rapidly filtered through diatomaceous earth. Theorganic layer is washed with an aqueous ammonium chloride solution,water, dried over magnesium sulfate and evaporated to dryness. The crudeproduct is dissolved in aqueous methanol containing a drop ofhydrochloric acid. The solution is stirred at room temperature for about1 hour and poured onto ice-water. The resulting oil is extracted intomethylenechloride, washed with water, dried over magnesium sulfate andthe solvent removed. The residue which remains is crystallized fromether-hexane to yield 7α-methyl-4-androstene-3,17,19-trione. The trioneso prepared is dissolved in ethanol and sodium borohydride added undernitrogen. Stirring is continued for about 1 hour, and the solutionpoured onto ice water containing a few drops at acetic acid. The solidwhich forms is filtered, dried and recrystallized from ethanol to yield7α-methyl-4-androstene-3β,17β,19-triol.

Substituting 4-methyl-4,6-androstadiene-3,17,19-trione,17β-hydroxy-17α-methyl-4,6-androstadiene-3,19-dione and17β-hydroxy-17α-propinyl-4,6-androstadiene-3,19-dione for the4,6-androstadiene-3,17,19-trione above results in the formation of4,7α-dimethyl-4-androstene-3β,17β,9-triol,7α,17α-dimethyl-4-androstene-3β,17β,19-triol and7α-methyl-17α-propinyl-4-androstene-3β,17β,19-triol, respectively.

EXAMPLE 59 17β,19-Dihydroxy-7α-methyl-4-methyl-4-androsten-3-one

7α-Methyl-4-androstene-3β,17β,19-triol is dissolved in hot chloroformand cooled to 15° C. Activated manganese dioxide is added at a rate suchthat the temperature does not rise above 25° C. Stirring is continued atroom temperature for about 1 hour, the manganese dioxide is removed byfiltration through a bed of diatomaceous earth and the chloroformdistilled under vacuum. The residue which remains is crystallized fromacetonitrile to yield 17β,19-dihydroxy-7α-methyl-4-androsten-3-one.

Substituting 4,7α-dimethyl-4-androstene-3β,17β,19-triol,7α,17α-dimethyl-4-androstene-3β,17β,19-triol and7α-methyl-17α-propinyl-4-androstene-3β,17β,19-triol for the7α-methyl-4-androstene-3β,17β,19-triol above results in the formation of17β,19-dihydroxy-4,7α-dimethyl-4-androsten-3-one,17β,19-dihydroxy-7α,17α-dimethyl-4-androsten-3-one,17β,19-dihydroxy-7α,17α-dimethyl-4-androsten-3-one and17β,19-dihydroxy-7α-methyl-17α-propinyl-4-androsten-3-one, respectively.

EXAMPLE 607α-Methyl-17β,19-di-(2'-tetrahydropyranyloxy)-4-androsten-3-one

To a stirred solution of 17β,19-dihydroxy-7α-methyl-4-androsten-3-oneand p-toluenesulfonic acid in anhydrous dioxane is added2,3-dihydropyran slowly. After 5 minutes, methanolic ammonia is addeduntil the solution is slightly basic. The solvent is removed undervacuum and the residual oil is dissolved in methylenechloride. Themethylenechloride solution is extracted with aqueous sodium bicarbonate,dried over sodium sulfate, and concentrated under vacuum. The residuewhich remains is crystallized from pentane to give7α-methyl-17β,19-di(2'-tetrahydropyranyloxy)-4-androsten-3-one.

EXAMPLE 61 17β,19-Dihydroxy-1,4,6-androstatrien-3-one diacetate

17,β,19-Dihydroxy-4-androsten-3-one diacetate and chloranil aredissolved in t-butanol which is rapidly brought to its refluxtemperature. The t-butanol is removed by distillation at atmosphericpressure at such a rate that the total reflux and distillation timeequals 1 hour. The dark residue which remains is triturated with hotchloroform and filtered. The filtrate is extracted with water, a 2%sodium hydroxide solution, again with water, dried over magnesiumsulfate and the solvent removed to yield17β,19-dihydroxy-4,6-androstadiene-3-one diacetate. The diene soprepared is refluxed with dichlorodicyanobenzoquinone in anhydrousdioxane for about 48 hours. The mixture is cooled, filtered and thefiltrate poured onto a mixture of methylenechloride and water. Theorganic layer is separated, washed with water, dried well over magnesiumsulfate and the solvent removed. The dark residue which remains ischromatographed on silica gel and eluted with methylenechloride to yieldthe desired 17β,19-dihydroxy-1,4,6-androstatrien-3-one diacetate.

EXAMPLE 62 17β,19-Dihydroxy-1α-methyl-4,6-androstadien-3-one diacetate

A solution of lithium dimethylcopper is prepared under nitrogen by theaddition of 1.6 M ethereal methyllithium to an ether slurry of cuprousiodide at 0° C. The solution is stirred at 0° C. for twenty minutes, asolution of 17β,19-dihydroxy-1,4,6-androstatrien-3-one diacetate inanhydrous tetrahydrofuran is added over a 20-minute period, and themixture stirred an additional 30 minutes. The reaction mixture is pouredonto a saturated aqueous ammonium chloride solution, benzene is addedand the resulting mixture filtered through a bed of diatomaceous earth.The organic layer is washed with aqueous ammonium chloride, water, driedover magnesium sulfate and evaporated to dryness. The residue remainingis crystallized from hexane to yield17β,19-dihydroxy-1α-methyl-1,4,6-androstadien-3-one diacetate.

EXAMPLE 63 17β,19-Dihydroxy-1α,7α-dimethyl-4-androsten-3-one diacetate

A solution of 17β,19-dihydroxy-1α-methyl-4,6-androstadien-3-onediacetate in anhydrous tetrahydrofuran is added slowly to an ice coldethereal solution of lithium dimethylcopper prepared as in the precedingExample. Stirring is continued for 30 minutes and the mixture is pouredonto a saturated aqueous ammonium chloride solution. Benzene is addedand the mixture filtered through a bed of diatomaceous earth. Theorganic layer is washed with aqueous ammonium chloride, water, driedover magnesium sulfate and evaporated to dryness. The residue is stirredat room temperature with aqueous methanolic hydrochloric acid for 1 hourand then poured onto ice water. The gum is extracted with ether, washedwith water, dried over magnesium sulfate and the ether removed. Theresidue is chromatographed on silica gel and eluted with benzene. Theeluant is recrystallized from hexane to give17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one diacetate.

EXAMPLE 64 17β,19-Dihydroxy-1α,7α-dimethyl-4-androsten-3-one

17β,19-Dihydroxy-1α,7α-dimethyl-4-androsten-3-one diacetate is dissolvedunder nitrogen in a sodium methoxide methanol solution at 0° C. andstirred at room temperature for about 2 hours. The solution is pouredonto water and the solid collected by filtration. Recrystallization ofthe solid from acetonitrile yields the desired17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one.

EXAMPLE 65 17β,19-Dihydroxy-1α,7α-dimethyl-4-androsten-3-one 17-acetate

To a solution of 17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-onediacetate in 10% aqueous methanol is added 1 equivalent of sodiumbicarbonate. The solution is heated at its reflux temperature for 1hour. Methanol is removed under vacuum to half volume and theconcentrate is poured onto water. The solid which forms is filtered, airdried and crystallized from hexane to yield17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one 17-acetate.

Substituting 17β,19-dihydroxy-1α-methyl-4-androsten-3-one diacetate and17β,19-dihydroxy-4-methyl-4-androsten-3-one diacetate for the17β,19-dihydroxy-1α,7α-dimethyl-4-androsten-3-one diacetate aboveresults in the preparation of17β,19-dihydroxy-1α-methyl-4-androsten-3-one 17-acetate and17β,19-dihydroxy-4-methyl-4-androsten-3-one 17-acetate.

EXAMPLE 66

The following Example is illustrative of the behavioral activity for thecompounds of this invention.

Copulatory behavioral tests are conducted in mature, sexuallyexperienced Sprague-Dawley male rats that were either intact, castratedor castrated-adrenalectomized. Castration and adrenalectomy reduces theeffect on behavior associated with endogenous steroids and/or theirmetabolites. The onset and intensity of behavioral responses related tomounting, intromission and ejaculation are determined both prior to andafter an interval of at least two weeks post-surgery. Five animals pergroup are subcutaneously administered 500 micrograms/kg of19-hydroxytestosterone, testosterone or 0.25 ml/kg of olive oil vehiclefor a period of 14 days. Ten minute behavioral observations are made inthe presence of a receptive female rat on days 2, 8, 12 and 15 of thetreatment period.

As shown in the table below, testosterone treatment in both castratedand adrenalectomized - castrated rats approaches that of pre-operativeand intact control levels of behavior by about day 12. In contrastthereto castrated - adrenalectomized rats treated with19-hydroxytestosterone had increases in behavioral parametersapproximately 24 hours after initial therapy. Furthermore, these animalsremain at this elevated level throughout the entire treatment period. Incastrated rats similar but less permanent effects are observed with theadministration of testosterone and 19-hydroxytestosterone.

    __________________________________________________________________________    MEAN NUMBER OF INTROMISSIONS                                                  AND PERCENT RESPONSE PER 10 MINUTE OBSERVATION PERIOD                                       Pre-Treatment                                                                             Treatment Period (14 days)                                        Pre   Post                                                                    Surgery                                                                             Surgery                                                                             2nd Day                                                                             8th Day                                                                             12th Day                                                                            15th Day                          Treatment     No.                                                                              %  No.                                                                              %  No.                                                                              %  No.                                                                              %  No.                                                                              %  No.                                                                              %                              __________________________________________________________________________    CASTRATED                                                                     Vehicle                                                                       (Olive oil)   9.2                                                                              100                                                                              3.0                                                                              40 0.0                                                                              0  2.4                                                                              40 1.4                                                                              40 0.6                                                                              40                             Testosterone                                                                  500 μg/kg s.c.                                                                           9.4                                                                              100                                                                              1.0                                                                              20 0.0                                                                              0  0.0                                                                               0 10.8                                                                             80 3.8                                                                              40                             19-Hydroxy-                                                                   testosterone                                                                  500 μg/kg s.c.                                                                           11.2                                                                             100                                                                              0.4                                                                              20 0.0                                                                              0  0.0                                                                               0 0.0                                                                               0 8.5                                                                              50                             ADRENALECTOMIZED -                                                            CASTRATED                                                                     Vehicle                                                                       (Olive oil)   15.6                                                                             100                                                                              7.0                                                                              80 0.0                                                                              0  1.2                                                                              20 *NT   2.4                                                                              40                             Testosterone                                                                  500 μg/kg s.c.                                                                           17.2                                                                             100                                                                              4.8                                                                              60 0.0                                                                              0  3.2                                                                              20 9.8                                                                              100                                                                              11.0                                                                             75                             19-Hydroxy-                                                                   testosterone                                                                  500 μg/kg s.c.                                                                           19.2                                                                             100                                                                              4.8                                                                              60 9.8                                                                              80 12.4                                                                             80 10.2                                                                             80 16.4                                                                             100                            INTACT                                                                        Vehicle                                                                       (Olive oil)   11.8                                                                             100                                                                              9.6                                                                              100                                                                              13.8                                                                             100                                                                              22.8                                                                             100                                                                              *NT   20.8                                                                             100                            __________________________________________________________________________     *NT = Not Tested                                                         

EXAMPLE 67 Preparation of a tablet formulation

One thousand tablets for oral use, each containing 25 mg of19-(1'-ethoxy-1'-cyclohexyloxy)-17-hydroxyandrost-4-en-3-one areprepared according to the following formulation:

    ______________________________________                                                                  Gm                                                  ______________________________________                                        (a)      19-(1'-ethoxy-1'-cyclohexyloxy)-17-                                           hydroxyandrost-4-en-3-one                                                                            25                                            (b)      Dicalcium phosphate    150                                           (c)      Methylcellulose, U.S.P. (15 cps)                                                                     6.5                                           (d)      Talc                   20                                            (e)      Calcium stearate       2.5                                           ______________________________________                                    

The 19-(1'-ethoxy-1'-cyclohexyloxy)-17-hydroxyandrost-4-en-3-one anddicalcium phosphate are mixed well, granulated with a 7.5% aqueoussolution of methylcellulose, passed through a No. 8 screen and carefullydried. The dried granules are passed through a No. 12 screen, blendedwith talc and calcium stearate and compressed into tablets.

EXAMPLE 68 Preparation of a capsule formulation

One thousand two-piece hard gelatin capsules for oral use eachcontaining 10 mg of17β,19-di-(2'-tetrahydropyranyloxy)-androst-4-en-3-one are prepared fromthe following ingredients:

    ______________________________________                                                                  Gm                                                  ______________________________________                                        (a)      17β,19-di-(2'-tetrahydropyranyloxy)-                                     androst-4-en-3-one     10                                            (b)      Lactose, U.S.P.        100                                           (c)      Starch, U.S.P.         10                                            (d)      Talc, U.S.P.           5                                             (e)      Calcium stearate       1                                             ______________________________________                                    

The finely powdered materials are mixed until uniformly dispersed andfilled into hard shelled gelatin capsules of the appropriate size.

In a similar fashion one-piece soft gelatin capsules can be prepared inwhich the above formulation can be granulated, slugged or compresseddirectly into a rotary die or plate mold in which the capsule is formed.Alternatively, the above excipients may be omitted and the activeingredient dispensed as a powder directly into the capsule.

EXAMPLE 69 Preparation of an intramuscular injection

A sterile aqueous suspension suitable for intramuscular injection isprepared from the following ingredients:

    ______________________________________                                                                   Gm                                                 ______________________________________                                        (a)     17α-ethinyl-17β-hydroxy-19-(1                                      ethoxy-1'-cyclopentyloxy)androst-                                             4-en-3-one               1                                            (b)     Polyethylene glycol 4000, U.S.P.                                                                       3                                            (c)     Sodium chloride          0.9                                          (d)     Polyoxyethylene derivatives of                                                sorbitan monooleate (TWEEN 80) U.S.P.                                                                  0.4                                          (e)     Sodium metabisulfite     0.1                                          (f)     Methylparaben, U.S.P.    0.18                                         (g)     Propylparaben, U.S.P.    0.02                                         (h)     Water for injection q.s. to 100 ml                                    ______________________________________                                    

The parabens, sodium metabisulfite and sodium chloride are dissolved inapproximately one-half the volume of water for injection at 80° C. withstirring. The solution is cooled to below 40° C. and the activeingredient is dissolved therein followed by the polyethylene glycol4,000 and polyoxyethylene derivatives of sorbitan monooleate. The cooledsolution is adjusted to the final volume with water for injection and isthen sterilized by sterile filtration through a suitable filter. Eachone ml of solution contains 10 mg of17α-ethinyl-17β-hydroxy-19-(1'-ethoxy-1'-cyclopentyloxy)androst-4-en-3-oneas the active ingredient.

We claim:
 1. An androst-4-en-19-ol having the formula ##STR3## whereinR₁ is selected from the group consisting of oxo and hydroxy;R₃ isselected from the group consisting of hydrogen, lower alkyl having from1 to 6 carbon atoms, lower alkenyl having from 2 to 6 carbon atoms andlower alkynyl having from 2 to 6 carbon atoms, and R₃ and OR₄ when takentogether is oxo; R₄ and R₅ are each selected from the group consistingof hydrogen, lower alkyl having from 1 to 3 carbon atoms, trialkylsilylin which the alkyl group has from 1 to 5 carbon atoms, triphenylsilyl,2-tetrahydropyranyl, 4-tetrahydropyranyl, 1-cycloalkenyl having from 5to 7 carbon atoms, 1-methoxycycloalkyl and 1-ethoxycycloalkyl in whichthe cycloalkyl group has from 5 to 7 carbon atoms, with the proviso thatR₄ and R₅ cannot both be hydrogen at the same time, and with the furtherproviso that when R₄ is 2-tetrahydropyranyl and R₆, R₇, R₈ and R₉ areall hydrogen, then R₃ and R₅ cannot both be hydrogen and R₁ cannot beoxo; R₆, R₇, R₈ and R₉ are hydrogen and methyl with the proviso thatwhen R₁ is oxo, R₄ is hydrogen, acyl or when taken together with R₃ isoxo, R₅ is hydrogen and R₉ is methyl, then R₆, R₇ and R₈ cannot all behydrogen at the same time.
 2. A compound according to claim 1 in whichR₁ is oxo and H(OR₂), R₂ is hydrogen, R₅ is hydrogen and R₄ is selectedfrom the group consisting of lower alkyl having from 1 to 3 carbonatoms, trialkylsilyl in which the alkyl group has from 1 to 5 carbonatoms, triphenylsilyl, 4-tetrahydropyranyl, 1-cycloalkenyl having from 5to 7 carbon atoms, 1-methoxycycloalkyl and 1-ethoxycycloalkyl in whichthe cycloalkyl group has from 5 to 7 carbon atoms.
 3. A compoundaccording to claim 1 in which R₁ is oxo and H(OR₂), R₂ is hydrogen, R₄is hydrogen and when taken together with R₃ is oxo, R₅ is selected fromthe group consisting of lower alkyl having from 1 to 3 carbon atoms,trialkylsilyl in which the alkyl group has from 1 to 5 carbon atoms,triphenylsilyl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 1-cycloalkenylhaving from 5 to 7 carbon atoms, 1-methoxycycloalkyl and1-ethoxycycloalkyl in which the cycloalkyl group has from 5 to 7 carbonatoms.
 4. A compound according to claim 1 in which R₁ is oxo and H(OR₂),R₂ is hydrogen and R₄ and R₅ are each selected from the group consistingof lower alkyl having from 1 to 3 carbon atoms, trialkylsilyl in whichthe alkyl group has from 1 to 5 carbon atoms, triphenylsilyl,2-tetrahydropyranyl, 4-tetrahydropyranyl, 1-cycloalkenyl having from 5to 7 carbon atoms, 1-methoxycycloalkyl and 1-ethoxycycloalkyl in whichthe cycloalkyl group has from 5 to 7 carbon atoms.